polysaccharide sulfate - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	polysaccharide sulfate	go back to main search page
Accession:	CHEBI:37944	browse the term
Definition:	Any carbohydrate sulfate that is a polysaccharide carrying at least one O-sulfo substituent.
Synonyms:	related_synonym:	polysaccharide sulfates

show annotations for term's descendants Sort by:
Rat (1666) Mouse (1918) Human (1677) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (6) Green Monkey (0) Naked Mole-rat (0) All
Genes (1918)

carrageenan

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

thymoma viral proto-oncogene 1

increases phosphorylation
multiple interactions

Carrageenan results in increased phosphorylation of AKT1 protein
fucoxanthin inhibits the reaction [Carrageenan results in increased phosphorylation of AKT1 protein]

NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318

G

albumin

decreases expression
multiple interactions

Carrageenan results in decreased expression of ALB protein
caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in decreased expression of ALB protein]; Indomethacin inhibits the reaction [Carrageenan results in decreased expression of ALB protein]

NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461

G

annexin A1

affects response to substance
multiple interactions

ANXA1 protein affects the susceptibility to Carrageenan
ANXA1 protein affects the susceptibility to [Dexamethasone co-treated with Carrageenan]

NCBI chr19:20,350,798...20,368,035
Ensembl chr19:20,350,792...20,368,308

G

amyloid P component, serum

increases expression

Carrageenan results in increased expression of APCS protein

NCBI chr 1:172,721,528...172,722,516
Ensembl chr 1:172,721,528...172,722,608

G

catalase

decreases activity
multiple interactions

Carrageenan results in decreased activity of CAT protein
caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in decreased activity of CAT protein]; Indomethacin inhibits the reaction [Carrageenan results in decreased activity of CAT protein]; procyanidin B2 inhibits the reaction [Carrageenan results in decreased activity of CAT protein]
fucoxanthin inhibits the reaction [Carrageenan results in decreased activity of CAT protein]

PMID:26418808 PMID:28844677 PMID:34789018

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

G

C-C motif chemokine ligand 2

multiple interactions
increases expression

5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid inhibits the reaction [Carrageenan results in increased expression of CCL2 protein]

PMID:12444156 PMID:20383154

NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279

G

C-C motif chemokine ligand 3

multiple interactions
increases expression

5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid inhibits the reaction [Carrageenan results in increased expression of CCL3 protein]

PMID:12444156 PMID:20383154

NCBI chr11:83,538,669...83,540,204
Ensembl chr11:83,538,670...83,540,181

G

C-C motif chemokine ligand 5

increases expression
multiple interactions

Carrageenan results in increased expression of CCL5 protein
isoquercitrin inhibits the reaction [Carrageenan results in increased expression of CCL5 protein]; Quercetin inhibits the reaction [Carrageenan results in increased expression of CCL5 protein]

PMID:12444156 PMID:14654164

NCBI chr11:83,416,604...83,421,344
Ensembl chr11:83,416,604...83,421,344

G

chymase 1, mast cell

multiple interactions
increases expression

adelmidrol inhibits the reaction [Carrageenan results in increased expression of CMA1 protein]

NCBI chr14:56,178,908...56,182,132
Ensembl chr14:56,178,908...56,182,132

G

C-reactive protein, pentraxin-related

multiple interactions
increases expression

caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of CRP protein]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of CRP protein]

NCBI chr 1:172,525,623...172,527,533
Ensembl chr 1:172,525,622...172,660,598

G

C-X-C motif chemokine ligand 15

multiple interactions
increases expression

3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [Carrageenan results in increased expression of CXCL8 mRNA]; 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [Carrageenan results in increased expression of CXCL8 protein]
Carrageenan results in increased expression of CXCL8 mRNA; Carrageenan results in increased expression of CXCL8 protein

NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926

G

C-X-C motif chemokine ligand 2

multiple interactions
increases secretion
increases expression

IMMLG5521 inhibits the reaction [Carrageenan results in increased secretion of CXCL2 protein]; isoquercitrin inhibits the reaction [Carrageenan results in increased expression of CXCL2 protein]

PMID:12444156 PMID:14654164 PMID:21549112

NCBI chr 5:91,051,758...91,053,797
Ensembl chr 5:91,051,730...91,053,797

G

C-X-C motif chemokine ligand 3

increases expression

Carrageenan results in increased expression of CXCL1 protein

NCBI chr 5:90,933,960...90,935,952
Ensembl chr 5:90,933,962...90,937,459

G

early growth response 1

increases expression
multiple interactions

Carrageenan results in increased expression of EGR1 protein
3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [Carrageenan results in increased expression of EGR1 protein]; EGR1 protein inhibits the reaction [Carrageenan results in decreased expression of and affects the localization of TJP1 protein]; NFKBIA protein inhibits the reaction [Carrageenan results in increased expression of EGR1 protein]

NCBI chr18:34,994,260...34,998,009
Ensembl chr18:34,992,876...34,998,037

G

FBJ osteosarcoma oncogene

multiple interactions
increases expression

3-(1,2,5,6-tetrahydropyrid-4-yl)pyrrolo(3,2-b)pyrid-5-one inhibits the reaction [Carrageenan results in increased expression of FOS protein]; Flurbiprofen inhibits the reaction [Carrageenan results in increased expression of FOS protein]; Flurbiprofen promotes the reaction [Urethane inhibits the reaction [Carrageenan results in increased expression of FOS protein]]; Urethane inhibits the reaction [Carrageenan results in increased expression of FOS protein]; Urethane inhibits the reaction [Flurbiprofen inhibits the reaction [Carrageenan results in increased expression of FOS protein]]

PMID:1327382 PMID:11164833

NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047

G

galanin and GMAP prepropeptide

decreases response to substance

GAL protein results in decreased susceptibility to Carrageenan

NCBI chr19:3,459,915...3,464,544
Ensembl chr19:3,459,915...3,464,544

G

G protein-coupled receptor 132

increases expression

Carrageenan results in increased expression of GPR132 mRNA

NCBI chr12:112,814,493...112,832,035
Ensembl chr12:112,814,493...112,831,848

G

G protein-coupled receptor 4

increases expression

Carrageenan results in increased expression of GPR4 mRNA

NCBI chr 7:18,946,463...18,958,101
Ensembl chr 7:18,946,463...18,958,099

G

G-protein coupled receptor 65

increases expression

Carrageenan results in increased expression of GPR65 mRNA

NCBI chr12:98,234,894...98,242,981
Ensembl chr12:98,234,894...98,242,903

G

heme oxygenase 1

multiple interactions
decreases expression

caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in decreased expression of HMOX1 mRNA]; Indomethacin inhibits the reaction [Carrageenan results in decreased expression of HMOX1 mRNA]; procyanidin B2 inhibits the reaction [Carrageenan results in decreased expression of HMOX1 protein]
Carrageenan results in decreased expression of HMOX1 mRNA; Carrageenan results in decreased expression of HMOX1 protein

PMID:28844677 PMID:34789018

NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217

G

heat shock protein 1A

increases expression

Carrageenan results in increased expression of HSPA1A protein

NCBI chr17:35,188,335...35,191,132
Ensembl chr17:35,188,166...35,191,132

G

intercellular adhesion molecule 1

multiple interactions
increases expression

bisphenol A diglycidyl ether inhibits the reaction [Rosiglitazone inhibits the reaction [Carrageenan results in increased expression of ICAM1 protein]]; caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of ICAM1 protein]; Carrageenan promotes the reaction [Lipopolysaccharides results in increased expression of ICAM1 mRNA]; Dexamethasone inhibits the reaction [Carrageenan results in increased expression of ICAM1 mRNA]; Fluvoxamine inhibits the reaction [Carrageenan results in increased expression of ICAM1 mRNA]; imisopasem manganese inhibits the reaction [Carrageenan results in increased expression of ICAM1 protein]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of ICAM1 protein]; Rosiglitazone inhibits the reaction [Carrageenan results in increased expression of ICAM1 protein]
Carrageenan results in increased expression of ICAM1 mRNA; Carrageenan results in increased expression of ICAM1 protein

PMID:11181422 PMID:14709329 PMID:22330755 PMID:27803785 PMID:34789018

NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113

G

interleukin 10

increases secretion
multiple interactions
increases expression

Carrageenan results in increased secretion of IL10 protein
indole-3-guanylhydrazone hydrochloride promotes the reaction [Carrageenan results in increased secretion of IL10 protein]; Indomethacin promotes the reaction [Carrageenan results in increased secretion of IL10 protein]
Indomethacin inhibits the reaction [Carrageenan results in increased expression of IL10 mRNA]; procyanidin B2 inhibits the reaction [Carrageenan results in increased secretion of IL10 protein]; Thioctic Acid promotes the reaction [Carrageenan results in increased expression of IL10 mRNA]

PMID:11181422 PMID:19735303 PMID:28844677 PMID:29499192

NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711

G

interleukin 1 alpha

multiple interactions
decreases expression

Carrageenan inhibits the reaction [Morphine results in decreased expression of IL1A protein]; Dexamethasone inhibits the reaction [Carrageenan inhibits the reaction [Morphine results in decreased expression of IL1A protein]]; Dexamethasone inhibits the reaction [Morphine inhibits the reaction [Carrageenan results in decreased expression of IL1A protein]]; Morphine inhibits the reaction [Carrageenan results in decreased expression of IL1A protein]; Naloxone inhibits the reaction [Carrageenan inhibits the reaction [Morphine results in decreased expression of IL1A protein]]; Naloxone inhibits the reaction [Morphine inhibits the reaction [Carrageenan results in decreased expression of IL1A protein]]

NCBI chr 2:129,141,530...129,151,892
Ensembl chr 2:129,141,530...129,151,892

G

interleukin 1 beta

increases secretion
increases expression
multiple interactions

Carrageenan results in increased secretion of IL1B protein
Carrageenan results in increased expression of IL1B mRNA; Carrageenan results in increased expression of IL1B protein
5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid inhibits the reaction [Carrageenan results in increased expression of IL1B protein]; indole-3-guanylhydrazone hydrochloride inhibits the reaction [Carrageenan results in increased secretion of IL1B protein]; Indomethacin inhibits the reaction [Carrageenan results in increased secretion of IL1B protein]
3-methylquercetin inhibits the reaction [Carrageenan results in increased expression of IL1B protein]; budlein A inhibits the reaction [Carrageenan results in increased secretion of IL1B protein]; caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of IL1B mRNA]; caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of IL1B protein]; Carrageenan promotes the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; Dexamethasone inhibits the reaction [Carrageenan results in increased expression of IL1B protein]; imisopasem manganese inhibits the reaction [Carrageenan results in increased expression of IL1B protein]; IMMLG5521 inhibits the reaction [Carrageenan results in increased secretion of IL1B protein]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of IL1B mRNA]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of IL1B protein]; N-(2-hydroxybenzoyl)tyramine inhibits the reaction [Carrageenan results in increased expression of IL1B protein]

PMID:11181422 PMID:16368644 PMID:17320857 PMID:20383154 PMID:21549112 More...

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

G

interleukin 6

multiple interactions
increases expression
increases secretion

5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid inhibits the reaction [Carrageenan results in increased expression of IL6 protein]
3-methylquercetin inhibits the reaction [Carrageenan results in increased expression of IL6 protein]; Carrageenan promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Diclofenac inhibits the reaction [Carrageenan results in increased expression of IL6 protein]; imisopasem manganese inhibits the reaction [Carrageenan results in increased expression of IL6 protein]; procyanidin B2 inhibits the reaction [Carrageenan results in increased secretion of IL6 protein]; Thiazolidines analog inhibits the reaction [Carrageenan results in increased expression of IL6 protein]

PMID:11181422 PMID:20383154 PMID:22330755 PMID:23774260 PMID:24412305 More...

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

mitogen-activated protein kinase 1

increases phosphorylation
multiple interactions

Carrageenan results in increased phosphorylation of MAPK1 protein
fucoxanthin inhibits the reaction [Carrageenan results in increased phosphorylation of MAPK1 protein]; Indomethacin inhibits the reaction [Carrageenan results in increased phosphorylation of MAPK1 protein]

NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317

G

mitogen-activated protein kinase 14

multiple interactions
increases expression

caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of MAPK14 mRNA]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of MAPK14 mRNA]

NCBI chr17:28,910,316...28,967,379
Ensembl chr17:28,910,303...28,967,380

G

mitogen-activated protein kinase 3

increases phosphorylation
multiple interactions

Carrageenan results in increased phosphorylation of MAPK3 protein
fucoxanthin inhibits the reaction [Carrageenan results in increased phosphorylation of MAPK3 protein]; Indomethacin inhibits the reaction [Carrageenan results in increased phosphorylation of MAPK3 protein]

NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991

G

matrix metallopeptidase 9

increases expression
multiple interactions

Carrageenan results in increased expression of MMP9 protein
adelmidrol inhibits the reaction [Carrageenan results in increased expression of MMP9 protein]

NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770

G

myeloperoxidase

multiple interactions
increases activity
increases expression

adelmidrol inhibits the reaction [Carrageenan results in increased activity of MPO protein]; arvelexin analog inhibits the reaction [Carrageenan results in increased expression of MPO protein]; caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of MPO mRNA]; Carrageenan inhibits the reaction [Raloxifene Hydrochloride results in increased activity of MPO protein]; Dexamethasone inhibits the reaction [Carrageenan results in increased activity of MPO protein]; Diclofenac inhibits the reaction [Carrageenan results in increased activity of MPO protein]; Ibuprofen inhibits the reaction [Carrageenan results in increased expression of MPO protein]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of MPO mRNA]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Carrageenan results in increased activity of MPO protein]; N-(2-hydroxybenzoyl)tyramine inhibits the reaction [Carrageenan results in increased activity of MPO protein]; Thiazolidines analog inhibits the reaction [Carrageenan results in increased activity of MPO protein]
Carrageenan results in increased expression of MPO mRNA; Carrageenan results in increased expression of MPO protein

PMID:9890637 PMID:15860553 PMID:18429935 PMID:23872256 PMID:24412305 More...

NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239

G

metallothionein 1

multiple interactions

[Methylnitrosourea co-treated with Carrageenan] results in increased expression of MT1 protein

NCBI chr 8:94,905,214...94,906,955
Ensembl chr 8:94,905,710...94,906,955

G

nuclear factor, erythroid derived 2, like 2

affects localization
decreases expression
multiple interactions

Carrageenan affects the localization of NFE2L2 protein
Carrageenan results in decreased expression of NFE2L2 mRNA
caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in decreased expression of NFE2L2 mRNA]; Indomethacin inhibits the reaction [Carrageenan results in decreased expression of NFE2L2 mRNA]; procyanidin B2 inhibits the reaction [Carrageenan affects the localization of NFE2L2 protein]

PMID:28844677 PMID:34789018

NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985

G

nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105

increases expression
multiple interactions

Carrageenan results in increased expression of NFKB1 mRNA
caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of NFKB1 mRNA]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of NFKB1 mRNA]

NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308

G

nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha

multiple interactions

NFKBIA protein inhibits the reaction [Carrageenan results in increased expression of EGR1 protein]

NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432

G

nerve growth factor

increases expression
multiple interactions

Carrageenan results in increased expression of NGF protein
Dexamethasone inhibits the reaction [Carrageenan results in increased expression of NGF protein]

NCBI chr 3:102,377,235...102,428,329
Ensembl chr 3:102,377,235...102,428,329

G

nitric oxide synthase 2, inducible

multiple interactions
increases expression
increases activity

adelmidrol inhibits the reaction [Carrageenan results in increased expression of NOS2 protein]; caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of NOS2 mRNA]; Carrageenan inhibits the reaction [Raloxifene Hydrochloride results in increased expression of NOS2 protein]; Carrageenan promotes the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; Dexamethasone inhibits the reaction [Carrageenan results in increased expression of NOS2 mRNA]; Dexamethasone inhibits the reaction [Carrageenan results in increased expression of NOS2 protein]; Fluvoxamine inhibits the reaction [Carrageenan results in increased expression of NOS2 mRNA]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of NOS2 mRNA]
fucoxanthin inhibits the reaction [Carrageenan results in increased expression of NOS2 protein]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of NOS2 protein]
Carrageenan results in increased activity of NOS2 protein
Carrageenan results in increased expression of NOS2 mRNA; Carrageenan results in increased expression of NOS2 protein

PMID:7542281 PMID:9890637 PMID:15860553 PMID:18429935 PMID:22330755 More...

NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080

G

NAD(P)H dehydrogenase, quinone 1

multiple interactions
decreases expression

procyanidin B2 inhibits the reaction [Carrageenan results in decreased expression of NQO1 protein]

NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838

G

opioid receptor, mu 1

decreases expression

Carrageenan results in decreased expression of OPRM1 protein

NCBI chr10:6,708,593...6,988,209
Ensembl chr10:6,708,506...6,988,198

G

purinergic receptor P2X, ligand-gated ion channel, 7

multiple interactions

[(N-(1-(((cyanoimino)(5-quinolinylamino) methyl) amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide) binds to and results in decreased activity of P2RX7 protein] which results in decreased susceptibility to Carrageenan

NCBI chr 5:122,781,990...122,830,399
Ensembl chr 5:122,781,974...122,829,495

G

platelet/endothelial cell adhesion molecule 1

multiple interactions
increases expression

adelmidrol inhibits the reaction [Carrageenan results in increased expression of PECAM1 protein]

NCBI chr11:106,545,039...106,606,107
Ensembl chr11:106,545,043...106,641,454

G

prostaglandin E synthase

multiple interactions
increases expression

arvelexin analog inhibits the reaction [Carrageenan results in increased expression of PTGES protein]

PMID:17258197 PMID:25451575

NCBI chr 2:30,779,483...30,793,309
Ensembl chr 2:30,779,483...30,819,875

G

prostaglandin E synthase 2

multiple interactions
increases activity

2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)octanoic acid inhibits the reaction [[Carrageenan results in increased activity of PTGES2 protein] which results in increased chemical synthesis of Dinoprostone]; [Carrageenan results in increased activity of PTGES2 protein] which results in increased chemical synthesis of Dinoprostone

NCBI chr 2:32,285,902...32,292,752
Ensembl chr 2:32,285,908...32,295,784

G

prostaglandin-endoperoxide synthase 2

multiple interactions
increases expression

3-methylquercetin inhibits the reaction [Carrageenan results in increased expression of PTGS2 protein]; caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; Carrageenan inhibits the reaction [Raloxifene Hydrochloride results in increased expression of PTGS2 protein]; Dexamethasone inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; dragon's blood inhibits the reaction [Carrageenan results in increased expression of PTGS2 protein]; Fluvoxamine inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; isoquercitrin inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; Ketorolac inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [Carrageenan results in increased expression of PTGS2 protein]]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [Carrageenan results in increased expression of PTGS2 protein]; nimesulide promotes the reaction [Carrageenan results in increased expression of PTGS2 protein]; Quercetin inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; Resveratrol inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; Thioctic Acid inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; triflusal inhibits the reaction [Carrageenan results in increased expression of PTGS2 protein]
fucoxanthin inhibits the reaction [Carrageenan results in increased expression of PTGS2 protein]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of PTGS2 protein]
Carrageenan results in increased expression of PTGS2 mRNA; Carrageenan results in increased expression of PTGS2 protein

PMID:10101034 PMID:14654164 PMID:15860553 PMID:17258197 PMID:18814970 More...

NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978

G

v-rel reticuloendotheliosis viral oncogene homolog A (avian)

increases phosphorylation
increases expression
increases localization
multiple interactions

Carrageenan results in increased phosphorylation of RELA protein
Carrageenan results in increased expression of RELA protein
Carrageenan results in increased localization of RELA protein
caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of RELA protein]; IMMLG5521 inhibits the reaction [Carrageenan results in increased localization of RELA protein]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of RELA protein]

PMID:21549112 PMID:22561171 PMID:34789018

NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158

G

selectin, platelet

increases expression
multiple interactions

Carrageenan results in increased expression of SELP protein
imisopasem manganese inhibits the reaction [Carrageenan results in increased expression of SELP protein]

NCBI chr 1:163,942,833...163,977,595
Ensembl chr 1:163,942,833...163,977,595

G

somatostatin receptor 4

decreases response to substance

SSTR4 results in decreased susceptibility to Carrageenan

NCBI chr 2:148,237,297...148,238,684
Ensembl chr 2:148,237,264...148,238,687

G

signal transducer and activator of transcription 3

multiple interactions
increases expression

caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of STAT3 mRNA]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of STAT3 mRNA]

NCBI chr11:100,777,632...100,830,447
Ensembl chr11:100,775,924...100,830,366

G

transforming growth factor, beta 1

increases secretion

Carrageenan results in increased secretion of TGFB1 protein

NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502

G

tight junction protein 1

multiple interactions

3-(4-methylphenylsulfonyl)-2-propenenitrile promotes the reaction [Carrageenan results in decreased expression of and affects the localization of TJP1 protein]; Carrageenan results in decreased expression of and affects the localization of TJP1 protein; EGR1 protein inhibits the reaction [Carrageenan results in decreased expression of and affects the localization of TJP1 protein]

NCBI chr 7:64,945,913...65,177,629
Ensembl chr 7:64,945,913...65,177,529

G

tumor necrosis factor

increases secretion
increases expression
multiple interactions

Carrageenan results in increased secretion of TNF protein
Carrageenan results in increased expression of TNF mRNA; Carrageenan results in increased expression of TNF protein
5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid inhibits the reaction [Carrageenan results in increased expression of TNF protein]; diaoxinxuekang inhibits the reaction [Carrageenan results in increased expression of TNF protein]; indole-3-guanylhydrazone hydrochloride inhibits the reaction [Carrageenan results in increased secretion of TNF protein]; Indomethacin inhibits the reaction [Carrageenan results in increased secretion of TNF protein]
3-methylquercetin inhibits the reaction [Carrageenan results in increased expression of TNF protein]; adelmidrol inhibits the reaction [Carrageenan results in increased expression of TNF protein]; budlein A inhibits the reaction [Carrageenan results in increased secretion of TNF protein]; caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of TNF mRNA]; caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of TNF protein]; Dexamethasone inhibits the reaction [Carrageenan results in increased expression of TNF protein]; imisopasem manganese inhibits the reaction [Carrageenan results in increased expression of TNF protein]; IMMLG5521 inhibits the reaction [Carrageenan results in increased secretion of TNF protein]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of TNF mRNA]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of TNF protein]; isoquercitrin inhibits the reaction [Carrageenan results in increased expression of TNF protein]; N-(2-hydroxybenzoyl)tyramine inhibits the reaction [Carrageenan results in increased expression of TNF protein]; procyanidin B2 inhibits the reaction [Carrageenan results in increased expression of TNF protein]; Quercetin inhibits the reaction [Carrageenan results in increased expression of TNF protein]; Rutin inhibits the reaction [Carrageenan results in increased expression of TNF protein]; Thiazolidines analog inhibits the reaction [Carrageenan results in increased expression of TNF protein]

PMID:11181422 PMID:12444156 PMID:14654164 PMID:16368644 PMID:17320857 More...

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

G

vascular cell adhesion molecule 1

increases expression
multiple interactions

Carrageenan results in increased expression of VCAM1 mRNA
Dexamethasone inhibits the reaction [Carrageenan results in increased expression of VCAM1 mRNA]; Fluvoxamine inhibits the reaction [Carrageenan results in increased expression of VCAM1 mRNA]

NCBI chr 3:115,903,669...115,923,337
Ensembl chr 3:115,903,598...115,923,337

dextran sulfate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

alanyl-tRNA synthetase domain containing 1

multiple interactions
increases expression

evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of AARSD1 protein]

NCBI chr11:101,297,489...101,308,422
Ensembl chr11:101,297,665...101,308,441

G

4-aminobutyrate aminotransferase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABAT mRNA

NCBI chr16:8,331,293...8,439,432
Ensembl chr16:8,331,293...8,439,432

G

ATP-binding cassette, sub-family A member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCA1 mRNA

NCBI chr 4:53,030,789...53,159,988
Ensembl chr 4:53,030,787...53,159,895

G

ATP-binding cassette, sub-family A member 17

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCA17 mRNA

NCBI chr17:24,483,231...24,570,079
Ensembl chr17:24,483,233...24,570,042

G

ATP-binding cassette, sub-family B member 11

decreases expression

Dextran Sulfate results in decreased expression of ABCB11 mRNA; Dextran Sulfate results in decreased expression of ABCB11 protein

NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958

G

ATP-binding cassette, sub-family B member 1A

multiple interactions
decreases expression
increases response to substance

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB1A mRNA; ABCB1A protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]
Dextran Sulfate results in decreased expression of ABCB1A mRNA
ABCB1A gene mutant form results in increased susceptibility to Dextran Sulfate

PMID:29950665 PMID:30102254 PMID:30701287 PMID:35093514

NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575

G

ATP-binding cassette, sub-family B member 1B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB1B mRNA; ABCB1B protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]

PMID:29950665 PMID:30701287

NCBI chr 5:8,848,147...8,916,314
Ensembl chr 5:8,848,147...8,916,315

G

ATP-binding cassette, sub-family B member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB4 mRNA

NCBI chr 5:8,943,614...9,009,226
Ensembl chr 5:8,943,717...9,009,231

G

ATP-binding cassette, sub-family B member 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB6 mRNA

NCBI chr 1:75,148,284...75,157,066
Ensembl chr 1:75,148,361...75,157,036

G

ATP-binding cassette, sub-family C member 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC10 mRNA

NCBI chr17:46,614,146...46,638,954
Ensembl chr17:46,614,147...46,639,278

G

ATP-binding cassette, sub-family member 2

decreases expression
affects response to substance
multiple interactions

Dextran Sulfate results in decreased expression of ABCC2 mRNA; Dextran Sulfate results in decreased expression of ABCC2 protein
ABCC2 protein affects the susceptibility to Dextran Sulfate
ABCC2 protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]

PMID:27580383 PMID:30701287

NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179

G

ATP-binding cassette, sub-family C member 3

decreases expression
affects response to substance
multiple interactions

Dextran Sulfate results in decreased expression of ABCC3 mRNA; Dextran Sulfate results in decreased expression of ABCC3 protein
ABCC3 protein affects the susceptibility to Dextran Sulfate
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC3 mRNA; ABCC3 protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]

PMID:27580383 PMID:29950665 PMID:30701287 PMID:38844255

NCBI chr11:94,234,121...94,283,843
Ensembl chr11:94,234,121...94,283,823

G

ATP-binding cassette, sub-family C member 4

multiple interactions
decreases expression

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of ABCC4 mRNA; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCC4 mRNA
Dextran Sulfate results in decreased expression of ABCC4 mRNA; Dextran Sulfate results in decreased expression of ABCC4 protein

PMID:26271895 PMID:27580383 PMID:29950665

NCBI chr14:118,720,104...118,945,475
Ensembl chr14:118,720,104...118,943,631

G

ATP-binding cassette, sub-family C member 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC5 mRNA

NCBI chr16:20,150,053...20,245,178
Ensembl chr16:20,150,053...20,245,144

G

ATP-binding cassette, sub-family C member 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC6 mRNA

NCBI chr 7:45,625,804...45,679,915
Ensembl chr 7:45,616,979...45,679,726

G

ATP-binding cassette, sub-family C member 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCC9 mRNA

NCBI chr 6:142,533,592...142,648,472
Ensembl chr 6:142,533,588...142,648,041

G

ATP-binding cassette, sub-family F member 2

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of ABCF2 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ABCF2 protein]

NCBI chr 5:24,770,339...24,782,465
Ensembl chr 5:24,770,343...24,782,465

G

ATP binding cassette subfamily G member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCG1 mRNA

NCBI chr17:31,276,668...31,336,958
Ensembl chr17:31,276,649...31,336,962

G

ATP binding cassette subfamily G member 2 (Junior blood group)

multiple interactions
decreases expression
affects response to substance

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCG2 mRNA; ABCG2 protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]
Dextran Sulfate results in decreased expression of ABCG2 mRNA
Dextran Sulfate results in decreased expression of ABCG2 mRNA; Dextran Sulfate results in decreased expression of ABCG2 protein
Rifampin promotes the reaction [Dextran Sulfate results in decreased expression of ABCG2 mRNA]
ABCG2 protein affects the susceptibility to Dextran Sulfate

PMID:29950665 PMID:30701287 PMID:38423481 PMID:38844255

NCBI chr 6:58,561,476...58,669,436
Ensembl chr 6:58,561,508...58,672,661

G

abl interactor 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of ABI1 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ABI1 protein]

NCBI chr 2:22,830,085...22,930,207
Ensembl chr 2:22,830,085...22,930,253

G

BRISC complex subunit

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of ABRAXAS2 protein
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of ABRAXAS2 protein]

NCBI chr 7:132,460,954...132,486,843
Ensembl chr 7:132,460,954...132,486,840

G

acetyl-Coenzyme A acyltransferase 1A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACAA1A mRNA

NCBI chr 9:119,170,113...119,179,361
Ensembl chr 9:119,168,742...119,179,365

G

acetyl-Coenzyme A acyltransferase 1B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACAA1B mRNA

NCBI chr 9:118,977,111...118,986,149
Ensembl chr 9:118,977,091...118,986,161

G

acetyl-CoA acyltransferase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACAA2 mRNA

NCBI chr18:74,912,283...74,939,278
Ensembl chr18:74,912,268...74,939,279

G

acetyl-Coenzyme A carboxylase alpha

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ACACA protein]

NCBI chr11:84,020,461...84,292,477
Ensembl chr11:84,020,498...84,292,477

G

acyl-Coenzyme A dehydrogenase, short chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACADS mRNA

NCBI chr 5:115,248,358...115,257,405
Ensembl chr 5:115,248,358...115,257,405

G

acyl-Coenzyme A dehydrogenase, short/branched chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACADSB mRNA

NCBI chr 7:131,012,330...131,047,940
Ensembl chr 7:131,012,330...131,050,673

G

ArfGAP with coiled-coil, ankyrin repeat and PH domains 2

increases expression
multiple interactions

Dextran Sulfate results in increased expression of ACAP2 protein
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of ACAP2 protein]

NCBI chr16:30,911,230...31,020,105
Ensembl chr16:30,911,230...31,020,063

G

angiotensin I converting enzyme

multiple interactions
increases abundance

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACE mRNA
dextran sodium sulfate increases abundance of Ace protein in small and large intestine extracellular space

CTD
RGD

PMID:29950665 PMID:26401072

NCBI chr11:105,858,774...105,880,790
Ensembl chr11:105,858,771...105,880,790

G

acetylcholinesterase

multiple interactions
decreases activity

[Chlorpyrifos co-treated with Dextran Sulfate] results in decreased activity of ACHE protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACHE mRNA
Dextran Sulfate results in decreased activity of ACHE protein

PMID:29950665 PMID:31226429 PMID:31807802

NCBI chr 5:137,286,516...137,292,728
Ensembl chr 5:137,285,781...137,292,728

G

atypical chemokine receptor 1 (Duffy blood group)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACKR1 mRNA

NCBI chr 1:173,159,457...173,161,079
Ensembl chr 1:173,159,453...173,161,317

G

atypical chemokine receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACKR2 mRNA

NCBI chr 9:121,727,421...121,740,177
Ensembl chr 9:121,727,421...121,740,140

G

atypical chemokine receptor 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACKR3 mRNA

NCBI chr 1:90,131,702...90,143,446
Ensembl chr 1:90,131,702...90,144,473

G

atypical chemokine receptor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACKR4 mRNA

NCBI chr 9:103,974,881...104,003,842
Ensembl chr 9:103,961,356...104,004,132

G

acid phosphatase 6, lysophosphatidic

multiple interactions
increases expression

evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of ACP6 protein]

NCBI chr 3:97,066,070...97,083,892
Ensembl chr 3:97,066,093...97,084,615

G

acyl-CoA synthetase bubblegum family member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACSBG2 mRNA

NCBI chr17:57,150,103...57,181,505
Ensembl chr17:57,150,103...57,181,447

G

acyl-CoA synthetase medium-chain family member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACSM1 mRNA

NCBI chr 7:119,217,035...119,261,738
Ensembl chr 7:119,206,249...119,261,738

G

acyl-CoA synthetase medium-chain family member 3

decreases expression
increases expression
multiple interactions

Dextran Sulfate results in decreased expression of ACSM3 protein
Dextran Sulfate results in increased expression of ACSM3 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ACSM3 protein]; evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of ACSM3 protein]

PMID:32272095 PMID:35362542

NCBI chr 7:119,360,106...119,384,119
Ensembl chr 7:119,360,146...119,386,736

G

acyl-CoA synthetase short-chain family member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACSS1 mRNA

NCBI chr 2:150,460,031...150,510,160
Ensembl chr 2:150,460,025...150,510,420

G

acyl-CoA synthetase short-chain family member 2

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACSS2 mRNA; evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of ACSS2 protein]

PMID:29950665 PMID:35362542

NCBI chr 2:155,359,963...155,404,663
Ensembl chr 2:155,359,868...155,427,644

G

actin-like 6A

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ACTL6A protein]

NCBI chr 3:32,762,695...32,781,122
Ensembl chr 3:32,760,447...32,781,122

G

actinin, alpha 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACTN1 mRNA

NCBI chr12:80,214,316...80,307,165
Ensembl chr12:80,214,321...80,307,145

G

actinin alpha 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACTN2 mRNA

NCBI chr13:12,284,312...12,355,613
Ensembl chr13:12,284,312...12,355,641

G

actin related protein 2

decreases expression

Dextran Sulfate results in decreased expression of ACTR2 protein

NCBI chr11:20,012,304...20,062,951
Ensembl chr11:20,012,304...20,062,913

G

ARP3 actin-related protein 3

decreases expression

Dextran Sulfate results in decreased expression of ACTR3 protein

NCBI chr 1:125,320,642...125,363,464
Ensembl chr 1:125,320,642...125,363,464

G

activin A receptor, type 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACVR1 mRNA

NCBI chr 2:58,336,450...58,456,840
Ensembl chr 2:58,278,656...58,457,169

G

aminoacylase 1

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of ACY1 protein

NCBI chr 9:106,310,180...106,315,594
Ensembl chr 9:106,310,180...106,315,518

G

adenosine deaminase

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ADA protein]

NCBI chr 2:163,565,703...163,592,154
Ensembl chr 2:163,568,504...163,592,159

G

a disintegrin and metallopeptidase domain 10

multiple interactions
increases expression

evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of ADAM10 protein]

NCBI chr 9:70,586,133...70,687,511
Ensembl chr 9:70,586,279...70,687,511

G

a disintegrin and metallopeptidase domain 17

multiple interactions
increases expression
affects response to substance

ADAM17 protein affects the reaction [Dextran Sulfate results in decreased expression of SIRT1 mRNA]; ADAM17 protein affects the reaction [Dextran Sulfate results in decreased expression of TIMP3 mRNA]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IFNG protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL17A protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL1B protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL6 protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of TNF protein]; resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of ADAM17 mRNA]
ADAM17 protein affects the susceptibility to Dextran Sulfate

NCBI chr12:21,373,510...21,423,633
Ensembl chr12:21,373,510...21,423,633

G

ADAM metallopeptidase with thrombospondin type 1 motif 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS1 mRNA

NCBI chr16:85,590,715...85,600,001
Ensembl chr16:85,590,715...85,600,001

G

ADAM metallopeptidase with thrombospondin type 1 motif 14

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS14 mRNA

NCBI chr10:61,032,886...61,109,447
Ensembl chr10:61,032,891...61,109,217

G

ADAM metallopeptidase with thrombospondin type 1 motif 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS2 mRNA

NCBI chr11:50,492,912...50,698,400
Ensembl chr11:50,492,911...50,698,400

G

ADAM metallopeptidase with thrombospondin type 1 motif 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS4 mRNA

NCBI chr 1:171,077,698...171,089,836
Ensembl chr 1:171,077,990...171,088,206

G

ADAM metallopeptidase with thrombospondin type 1 motif 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS5 mRNA

NCBI chr16:85,655,045...85,698,013
Ensembl chr16:85,653,061...85,698,716

G

adenylate cyclase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCY2 mRNA

NCBI chr13:68,768,162...69,147,719
Ensembl chr13:68,768,162...69,147,660

G

adenylate cyclase 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCY4 mRNA

NCBI chr14:56,006,513...56,021,552
Ensembl chr14:56,006,514...56,021,552

G

adenylate cyclase 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADCY6 mRNA

NCBI chr15:98,484,982...98,508,119
Ensembl chr15:98,487,854...98,507,957

G

adenylate cyclase 7

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCY7 mRNA
Dextran Sulfate results in decreased expression of ADCY7 mRNA

PMID:29950665 PMID:35093514

NCBI chr 8:88,998,818...89,056,593
Ensembl chr 8:88,999,031...89,056,590

G

adenylate cyclase activating polypeptide 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCYAP1 mRNA

NCBI chr17:93,506,448...93,513,967
Ensembl chr17:93,506,445...93,513,965

G

adenylate cyclase activating polypeptide 1 receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADCYAP1R1 mRNA

NCBI chr 6:55,428,486...55,478,440
Ensembl chr 6:55,428,963...55,478,436

G

adhesion G protein-coupled receptor A2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRA2 mRNA

NCBI chr 8:27,575,546...27,613,464
Ensembl chr 8:27,575,611...27,613,464

G

adhesion G protein-coupled receptor B1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADGRB1 mRNA

NCBI chr15:74,388,045...74,461,314
Ensembl chr15:74,388,044...74,461,314

G

adhesion G protein-coupled receptor E1

increases expression
multiple interactions

Dextran Sulfate results in increased expression of ADGRE1 protein
flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of ADGRE1 protein]

NCBI chr17:57,665,650...57,790,527
Ensembl chr17:57,665,691...57,790,527

G

adhesion G protein-coupled receptor E5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRE5 mRNA

NCBI chr 8:84,449,874...84,467,812
Ensembl chr 8:84,449,880...84,467,955

G

adhesion G protein-coupled receptor F1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRF1 mRNA

NCBI chr17:43,581,174...43,636,767
Ensembl chr17:43,581,220...43,635,628

G

adhesion G protein-coupled receptor F5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRF5 mRNA

NCBI chr17:43,671,225...43,770,448
Ensembl chr17:43,671,342...43,770,448

G

alcohol dehydrogenase 1 (class I)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADH1 mRNA

NCBI chr 3:137,983,346...137,996,459
Ensembl chr 3:137,966,752...137,996,459

G

alcohol dehydrogenase 5 (class III), chi polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADH5 mRNA

NCBI chr 3:138,142,961...138,161,260
Ensembl chr 3:138,148,854...138,161,260

G

adrenomedullin

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADM mRNA
Dextran Sulfate results in increased expression of ADM mRNA

PMID:29950665 PMID:35093514

NCBI chr 7:110,226,864...110,229,027
Ensembl chr 7:110,226,868...110,229,027

G

adenosine A2a receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADORA2A mRNA

NCBI chr10:75,152,711...75,170,626
Ensembl chr10:75,152,711...75,170,618

G

adenosine A2b receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of ADORA2B mRNA

NCBI chr11:62,139,810...62,157,278
Ensembl chr11:62,139,810...62,157,279

G

adenosine A3 receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADORA3 mRNA

NCBI chr 3:105,811,737...105,816,244
Ensembl chr 3:105,778,174...105,816,242

G

adrenergic receptor, alpha 2a

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADRA2A mRNA

NCBI chr19:54,033,690...54,037,413
Ensembl chr19:54,032,582...54,037,413

G

adrenergic receptor, beta 2

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of ADRB2 mRNA; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADRB2 mRNA

PMID:26271895 PMID:29950665

NCBI chr18:62,310,784...62,313,052
Ensembl chr18:62,310,887...62,313,030

G

angiotensinogen

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AGT mRNA
Dextran Sulfate results in decreased expression of AGT mRNA

PMID:29950665 PMID:35093514

NCBI chr 8:125,283,326...125,296,445
Ensembl chr 8:125,283,273...125,296,445

G

AHNAK nucleoprotein

decreases expression

Dextran Sulfate results in decreased expression of AHNAK mRNA

NCBI chr19:8,966,640...9,054,299
Ensembl chr19:8,966,648...9,054,278

G

aryl-hydrocarbon receptor

increases response to substance
multiple interactions

AHR gene mutant form results in increased susceptibility to Dextran Sulfate
AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of CXCL1 mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of CXCL2 mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of IL17A mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of LCN2 mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA]

NCBI chr12:35,547,978...35,584,988
Ensembl chr12:35,547,973...35,585,037

G

alpha hemoglobin stabilizing protein

decreases expression

Dextran Sulfate results in decreased expression of AHSP protein

NCBI chr 7:127,902,016...127,902,926
Ensembl chr 7:127,901,969...127,902,930

G

aryl-hydrocarbon receptor-interacting protein

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of AIP protein
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of AIP protein]

NCBI chr19:4,163,756...4,177,233
Ensembl chr19:4,164,446...4,175,858

G

adenylate kinase 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of AK1 protein
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of AK1 protein

NCBI chr 2:32,511,770...32,525,070
Ensembl chr 2:32,511,770...32,525,070

G

A kinase anchor protein 12

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AKAP12 mRNA; evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of AKAP12 protein]

PMID:29950665 PMID:35362542

NCBI chr10:4,216,329...4,309,471
Ensembl chr10:4,216,380...4,309,470

G

A kinase anchor protein 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AKAP5 mRNA

NCBI chr12:76,371,652...76,380,925
Ensembl chr12:76,371,665...76,380,927

G

A kinase anchor protein 8

multiple interactions
increases expression

evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of AKAP8 protein]

NCBI chr17:32,522,646...32,540,212
Ensembl chr17:32,522,646...32,540,212

G

aldo-keto reductase family 1 member B

decreases expression
multiple interactions
increases expression

Dextran Sulfate results in decreased expression of AKR1B1 protein
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AKR1B1 mRNA
Dextran Sulfate results in increased expression of AKR1B1 mRNA

PMID:29950665 PMID:35093514 PMID:35999755

NCBI chr 6:34,280,865...34,294,424
Ensembl chr 6:34,279,369...34,294,413

G

aldo-keto reductase family 1, member C12

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AKR1C12 mRNA

NCBI chr13:4,318,171...4,329,398
Ensembl chr13:4,318,175...4,329,432

G

aldo-keto reductase family 1, member C13

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AKR1C13 mRNA

NCBI chr13:4,241,167...4,255,601
Ensembl chr13:4,241,149...4,255,595

G

aldo-keto reductase family 1, member C14

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AKR1C14 mRNA

NCBI chr13:4,099,015...4,140,569
Ensembl chr13:4,099,011...4,140,688

G

aldo-keto reductase family 1, member C18

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AKR1C18 mRNA

NCBI chr13:4,182,614...4,200,645
Ensembl chr13:4,182,614...4,200,653

G

aldo-keto reductase family 1, member C19

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AKR1C19 mRNA

NCBI chr13:4,283,499...4,298,360
Ensembl chr13:4,278,699...4,302,842

G

thymoma viral proto-oncogene 1

multiple interactions

[APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein]
banxia xiexin decoction inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased phosphorylation of AKT1 protein]; Dextran Sulfate results in increased expression of and results in increased phosphorylation of AKT1 protein; palmatine inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased phosphorylation of AKT1 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased phosphorylation of AKT1 protein]

PMID:26262998 PMID:36806191

NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318

G

albumin

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of ALB protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALB mRNA

PMID:29950665 PMID:35999755

NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461

G

aldehyde dehydrogenase family 1, subfamily A1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH1A1 mRNA

NCBI chr19:20,469,947...20,620,827
Ensembl chr19:20,470,079...20,620,829

G

aldehyde dehydrogenase family 1, subfamily A7

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH1A7 mRNA
Dextran Sulfate results in decreased expression of ALDH1A7 mRNA

PMID:29950665 PMID:35093514

NCBI chr19:20,670,318...20,704,920
Ensembl chr19:20,670,317...20,704,926

G

aldehyde dehydrogenase 1 family, member B1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH1B1 mRNA

NCBI chr 4:45,799,022...45,804,608
Ensembl chr 4:45,799,022...45,804,604

G

aldehyde dehydrogenase 2, mitochondrial

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH2 mRNA

NCBI chr 5:121,704,090...121,731,887
Ensembl chr 5:121,704,090...121,731,887

G

aldehyde dehydrogenase family 3, subfamily A2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH3A2 mRNA

NCBI chr11:61,114,240...61,158,267
Ensembl chr11:61,114,243...61,158,290

G

aldehyde dehydrogenase family 7, member A1

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ALDH7A1 protein]

NCBI chr18:56,657,794...56,706,112
Ensembl chr18:56,642,759...56,706,023

G

aldolase C, fructose-bisphosphate

decreases expression
increases expression
multiple interactions

Dextran Sulfate results in decreased expression of ALDOA protein; Dextran Sulfate results in decreased expression of ALDOC mRNA
Dextran Sulfate results in increased expression of ALDOC protein
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of ALDOC protein]

PMID:35093514 PMID:35362542 PMID:35999755

NCBI chr11:78,213,899...78,218,607
Ensembl chr11:78,213,794...78,218,607

G

arachidonate 12-lipoxygenase

decreases expression

Dextran Sulfate results in decreased expression of ALOX12 protein

NCBI chr11:70,132,283...70,146,206
Ensembl chr11:70,132,283...70,146,179

G

arachidonate 12-lipoxygenase, 12R type

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALOX12B mRNA

NCBI chr11:69,047,898...69,060,617
Ensembl chr11:69,047,815...69,060,618

G

arachidonate 5-lipoxygenase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALOX5 mRNA

NCBI chr 6:116,387,030...116,438,139
Ensembl chr 6:116,387,038...116,438,139

G

arachidonate 5-lipoxygenase activating protein

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALOX5AP mRNA

NCBI chr 5:149,201,814...149,224,963
Ensembl chr 5:149,201,577...149,224,963

G

alkaline phosphatase, liver/bone/kidney

multiple interactions
increases activity

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALPL mRNA
Dextran Sulfate results in increased activity of ALPL protein

PMID:29950665 PMID:30489199

NCBI chr 4:137,469,042...137,523,695
Ensembl chr 4:137,469,044...137,523,695

G

adenosine monophosphate deaminase 3

increases expression
multiple interactions

Dextran Sulfate results in increased expression of AMPD3 protein
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of AMPD3 protein]

NCBI chr 7:110,367,291...110,411,612
Ensembl chr 7:110,367,413...110,411,612

G

angiopoietin 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANGPT4 mRNA

NCBI chr 2:151,753,127...151,787,257
Ensembl chr 2:151,753,130...151,787,257

G

angiopoietin-like 4

increases expression

Dextran Sulfate results in increased expression of ANGPTL4 mRNA

NCBI chr17:33,993,874...34,000,549
Ensembl chr17:33,992,724...34,000,804

G

anoctamin 1, calcium activated chloride channel

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANO1 mRNA

NCBI chr 7:144,142,286...144,305,762
Ensembl chr 7:144,142,286...144,305,711

G

anoctamin 10

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANO10 mRNA; evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of ANO10 protein]

PMID:29950665 PMID:35362542

NCBI chr 9:122,004,958...122,123,440
Ensembl chr 9:122,004,940...122,123,489

G

anoctamin 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANO6 mRNA

NCBI chr15:95,688,724...95,873,353
Ensembl chr15:95,688,724...95,872,632

G

anoctamin 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANO7 mRNA

NCBI chr 1:93,301,518...93,332,026
Ensembl chr 1:93,301,652...93,332,025

G

anoctamin 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANO9 mRNA

NCBI chr 7:140,681,125...140,697,719
Ensembl chr 7:140,681,125...140,697,719

G

annexin A1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANXA1 mRNA

NCBI chr19:20,350,798...20,368,035
Ensembl chr19:20,350,792...20,368,308

G

annexin A4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANXA4 mRNA

NCBI chr 6:86,713,822...86,770,616
Ensembl chr 6:86,713,822...86,770,566

G

adaptor-related protein complex AP-1, mu subunit 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AP1M1 mRNA

NCBI chr 8:72,993,857...73,011,230
Ensembl chr 8:72,993,862...73,011,229

G

adaptor protein complex AP-1, sigma 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of AP1S1 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of AP1S1 protein]

NCBI chr 5:137,063,852...137,074,917
Ensembl chr 5:137,063,847...137,074,989

G

adaptor-related protein complex 3, mu 1 subunit

multiple interactions
decreases expression

evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of AP3M1 protein]

NCBI chr14:21,083,810...21,102,603
Ensembl chr14:21,081,510...21,102,576

G

APC, WNT signaling pathway regulator

affects response to substance
multiple interactions

APC affects the susceptibility to Dextran Sulfate; APC protein affects the susceptibility to Dextran Sulfate
[APC protein affects the susceptibility to Dextran Sulfate] which affects the activity of MPO protein; [APC protein affects the susceptibility to Dextran Sulfate] which results in increased chemical synthesis of PTEN protein modified form; [APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein; PDE4B protein affects the reaction [APC protein affects the susceptibility to Dextran Sulfate]; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which affects the activity of MPO protein]; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which results in increased chemical synthesis of PTEN protein modified form]; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein]

PMID:16049979 PMID:26262998 PMID:30188895

NCBI chr18:34,353,350...34,455,243
Ensembl chr18:34,353,977...34,455,605

G

amyloid P component, serum

increases expression

Dextran Sulfate results in increased expression of APCS protein

NCBI chr 1:172,721,528...172,722,516
Ensembl chr 1:172,721,528...172,722,608

G

apelin

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of APLN mRNA
Dextran Sulfate results in decreased expression of APLN mRNA

PMID:29950665 PMID:35093514

NCBI chr X:47,114,023...47,123,730
Ensembl chr X:47,114,023...47,123,730

G

apolipoprotein A-II

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of APOA2 protein

NCBI chr 1:171,049,133...171,053,948
Ensembl chr 1:171,052,623...171,053,948

G

apolipoprotein A-IV

multiple interactions
decreases expression

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of APOA4 protein; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of APOA4 protein]

PMID:32272095 PMID:35999755

NCBI chr 9:46,152,142...46,154,756
Ensembl chr 9:46,151,994...46,154,757

G

apolipoprotein B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of APOB mRNA

NCBI chr12:8,027,629...8,066,839
Ensembl chr12:8,027,648...8,066,835

G

apolipoprotein C2

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of APOC2 protein

NCBI chr 7:19,405,504...19,411,866
Ensembl chr 7:19,405,504...19,411,866

G

apolipoprotein E

multiple interactions
decreases expression
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of APOE protein]; evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of APOE protein]

PMID:32272095 PMID:35362542

NCBI chr 7:19,430,169...19,434,326
Ensembl chr 7:19,430,034...19,433,113

G

apolipoprotein L 10A

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of APOL10A protein
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of APOL10A protein]

NCBI chr15:77,361,153...77,375,269
Ensembl chr15:77,361,247...77,375,269

G

amyloid beta precursor protein

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of APP mRNA

NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654

G

adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper containing 2

multiple interactions
increases expression

evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of APPL2 protein]

NCBI chr10:83,435,897...83,484,741
Ensembl chr10:83,435,897...83,484,602

G

aquaporin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AQP1 mRNA

NCBI chr 6:55,313,284...55,325,540
Ensembl chr 6:55,313,417...55,325,540

G

aquaporin 11

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AQP11 mRNA

NCBI chr 7:97,375,586...97,387,454
Ensembl chr 7:97,373,213...97,387,496

G

aquaporin 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AQP2 mRNA

NCBI chr15:99,476,937...99,482,426
Ensembl chr15:99,476,936...99,482,428

G

aquaporin 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AQP3 mRNA

NCBI chr 4:41,092,724...41,098,183
Ensembl chr 4:41,092,722...41,098,183

G

aquaporin 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AQP8 mRNA

NCBI chr 7:123,061,517...123,067,226
Ensembl chr 7:123,061,514...123,067,227

G

aquaporin 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AQP9 mRNA

NCBI chr 9:71,017,941...71,075,170
Ensembl chr 9:71,017,941...71,075,964

G

androgen receptor

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AR mRNA
Dextran Sulfate results in increased expression of AR mRNA

PMID:27920257 PMID:29950665

NCBI chr X:97,192,363...97,366,824
Ensembl chr X:97,192,375...97,366,821

G

ARF GTPase 3

decreases expression

Dextran Sulfate results in decreased expression of ARF3 protein

NCBI chr15:98,635,505...98,660,999
Ensembl chr15:98,634,515...98,661,095

G

ARF GTPase activating protein 2

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of ARFGAP2 protein
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of ARFGAP2 protein]

NCBI chr 2:91,095,460...91,107,716
Ensembl chr 2:91,095,319...91,107,276

G

arginase, liver

multiple interactions
decreases expression

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 mRNA; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 protein; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]]; IRF4 protein promotes the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]; IRF4 protein promotes the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 protein]
Dextran Sulfate results in decreased expression of ARG1 mRNA; Dextran Sulfate results in decreased expression of ARG1 protein

PMID:25026504 PMID:38164749

NCBI chr10:24,791,105...24,803,368
Ensembl chr10:24,791,119...24,803,382

G

Rho GTPase activating protein 1

decreases expression

Dextran Sulfate results in decreased expression of ARHGAP1 protein

NCBI chr 2:91,480,463...91,502,670
Ensembl chr 2:91,480,205...91,502,671

G

Rho GTPase activating protein 15

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGAP15 mRNA

NCBI chr 2:43,638,786...44,285,965
Ensembl chr 2:43,638,836...44,285,965

G

Rho GTPase activating protein 20

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARHGAP20 mRNA

NCBI chr 9:51,676,651...51,765,158
Ensembl chr 9:51,676,637...51,765,156

G

Rho GTPase activating protein 25

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGAP25 mRNA

NCBI chr 6:87,435,526...87,510,241
Ensembl chr 6:87,435,527...87,510,241

G

Rho GTPase activating protein 40

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARHGAP40 mRNA

NCBI chr 2:158,354,682...158,392,786
Ensembl chr 2:158,354,716...158,392,682

G

Rho GDP dissociation inhibitor alpha

decreases expression

Dextran Sulfate results in decreased expression of ARHGDIA protein

NCBI chr11:120,468,925...120,472,450
Ensembl chr11:120,468,930...120,472,450

G

Rho, GDP dissociation inhibitor beta

increases expression
decreases expression
multiple interactions

Dextran Sulfate results in increased expression of ARHGDIB mRNA
Dextran Sulfate results in decreased expression of ARHGDIB protein
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGDIB mRNA

PMID:23894361 PMID:29950665 PMID:35999755

NCBI chr 6:136,900,653...136,918,895
Ensembl chr 6:136,900,653...136,918,897

G

Rho guanine nucleotide exchange factor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGEF1 mRNA

NCBI chr 7:24,601,762...24,626,019
Ensembl chr 7:24,602,337...24,626,019

G

Rho guanine nucleotide exchange factor 12

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARHGEF12 mRNA

NCBI chr 9:42,875,138...43,017,069
Ensembl chr 9:42,875,138...43,018,534

G

Rac/Cdc42 guanine nucleotide exchange factor 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGEF6 mRNA

NCBI chr X:56,276,845...56,384,119
Ensembl chr X:56,276,845...56,384,089

G

ADP-ribosylation factor-like 3

increases expression
decreases expression
multiple interactions

Dextran Sulfate results in increased expression of ARL3 mRNA
Dextran Sulfate results in decreased expression of ARL3 protein
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of ARL3 protein]

PMID:35093514 PMID:35362542

NCBI chr19:46,519,548...46,561,621
Ensembl chr19:46,519,535...46,561,637

G

ADP-ribosylation factor-like 9

increases expression

Dextran Sulfate results in increased expression of ARL9 mRNA

NCBI chr 5:77,146,054...77,158,806
Ensembl chr 5:77,151,902...77,158,453

G

actin related protein 2/3 complex, subunit 2

decreases expression

Dextran Sulfate results in decreased expression of ARPC2 protein

NCBI chr 1:74,275,656...74,307,368
Ensembl chr 1:74,275,243...74,307,368

G

actin related protein 2/3 complex, subunit 3

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of ARPC3 protein
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of ARPC3 protein

NCBI chr 5:122,529,941...122,544,244
Ensembl chr 5:122,529,941...122,552,247

G

actin related protein 2/3 complex, subunit 4

decreases expression

Dextran Sulfate results in decreased expression of ARPC4 protein

NCBI chr 6:113,355,074...113,367,408
Ensembl chr 6:113,355,076...113,367,409

G

actin related protein 2/3 complex, subunit 5

increases expression
multiple interactions

Dextran Sulfate results in increased expression of ARPC5 protein
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of ARPC5 protein]

NCBI chr 1:152,642,293...152,651,331
Ensembl chr 1:152,642,293...152,651,348

G

arrestin, beta 2

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of ARRB2 mRNA

NCBI chr11:70,323,051...70,331,654
Ensembl chr11:70,323,461...70,331,654

G

arylsulfatase B

decreases expression

Dextran Sulfate results in decreased expression of ARSB mRNA

NCBI chr13:93,908,187...94,079,524
Ensembl chr13:93,908,138...94,079,524

G

ankyrin repeat and SOCS box-containing 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ASB2 mRNA

NCBI chr12:103,287,401...103,322,260
Ensembl chr12:103,287,401...103,322,260

G

acid-sensing ion channel family member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ASIC4 mRNA

NCBI chr 1:75,426,467...75,450,984
Ensembl chr 1:75,427,080...75,450,987

G

argininosuccinate synthetase 1

decreases expression

Dextran Sulfate results in decreased expression of ASS1 mRNA

NCBI chr 2:31,360,282...31,410,682
Ensembl chr 2:31,360,219...31,410,684

G

autophagy related 5

multiple interactions
increases expression

2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]]; 6-formylindolo(3,2-b)carbazole promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]; [Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of ATG5 mRNA; alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]]; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein]]; Leucine inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]]; obeticholic acid inhibits the reaction [[Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of ATG5 mRNA]

PMID:27611972 PMID:31676321 PMID:35439472

NCBI chr10:44,144,325...44,240,295
Ensembl chr10:44,144,354...44,240,287

G

autophagy related 7

multiple interactions
increases expression

2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]]; 6-formylindolo(3,2-b)carbazole promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]; alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]; Leucine inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]]

NCBI chr 6:114,620,075...114,837,565
Ensembl chr 6:114,620,058...114,837,575

G

5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase

decreases expression

Dextran Sulfate results in decreased expression of ATIC protein

NCBI chr 1:71,596,315...71,618,562
Ensembl chr 1:71,596,309...71,618,790

G

ATPase, class V, type 10A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP10A mRNA

NCBI chr 7:58,305,896...58,479,783
Ensembl chr 7:58,305,914...58,479,168

G

ATPase, class VI, type 11B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP11B mRNA

NCBI chr 3:35,808,104...35,910,425
Ensembl chr 3:35,808,255...35,910,425

G

ATPase, H+/K+ transporting, nongastric, alpha polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP12A mRNA

NCBI chr14:56,602,525...56,626,008
Ensembl chr14:56,602,525...56,626,007

G

ATPase, Na+/K+ transporting, alpha 1 polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP1A1 mRNA

NCBI chr 3:101,483,535...101,512,023
Ensembl chr 3:101,483,535...101,512,000

G

ATPase, Na+/K+ transporting, alpha 3 polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP1A3 mRNA

NCBI chr 7:24,677,592...24,705,338
Ensembl chr 7:24,677,592...24,705,383

G

ATPase, Na+/K+ transporting, alpha 4 polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP1A4 mRNA

NCBI chr 1:172,051,075...172,085,991
Ensembl chr 1:172,051,080...172,085,981

G

ATPase, Na+/K+ transporting, beta 1 polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP1B1 mRNA

NCBI chr 1:164,264,668...164,285,924
Ensembl chr 1:164,264,678...164,285,924

G

ATPase, Na+/K+ transporting, beta 3 polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP1B3 mRNA

NCBI chr 9:96,214,708...96,246,368
Ensembl chr 9:96,214,708...96,246,495

G

ATPase, Ca++ transporting, cardiac muscle, fast twitch 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP2A1 mRNA

NCBI chr 7:126,045,032...126,062,245
Ensembl chr 7:126,045,030...126,062,280

G

ATPase, Ca++ transporting, ubiquitous

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP2A3 mRNA

NCBI chr11:72,851,995...72,883,869
Ensembl chr11:72,851,995...72,883,870

G

ATPase, Ca++ transporting, plasma membrane 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP2B1 mRNA

NCBI chr10:98,750,243...98,862,005
Ensembl chr10:98,750,268...98,862,005

G

ATPase, Ca++ transporting, type 2C, member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of ATP2C2 mRNA

NCBI chr 8:120,426,748...120,484,457
Ensembl chr 8:120,426,748...120,484,456

G

ATPase, H+/K+ exchanging, beta polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP4B mRNA

NCBI chr 8:13,436,209...13,446,778
Ensembl chr 8:13,436,205...13,446,825

G

ATP synthase membrane subunit f

multiple interactions
decreases expression

evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of ATP5MF protein]

NCBI chr 5:145,120,514...145,128,351
Ensembl chr 5:145,120,508...145,128,872

G

ATPase, H+ transporting, lysosomal V0 subunit A2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP6V0A2 mRNA

NCBI chr 5:124,767,117...124,801,519
Ensembl chr 5:124,766,641...124,801,519

G

ATPase, H+ transporting, lysosomal V0 subunit A4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP6V0A4 mRNA

NCBI chr 6:38,025,418...38,101,521
Ensembl chr 6:38,025,418...38,101,521

G

ATPase, H+ transporting, lysosomal V0 subunit C

multiple interactions
decreases expression

evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of ATP6V0C protein]

NCBI chr17:24,382,839...24,388,652
Ensembl chr17:24,382,840...24,388,676

G

ATPase, H+ transporting, lysosomal V0 subunit D1

increases expression
multiple interactions

Dextran Sulfate results in increased expression of ATP6V0D1 protein
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of ATP6V0D1 protein]

NCBI chr 8:106,251,093...106,292,696
Ensembl chr 8:106,251,097...106,292,679

G

ATPase, H+ transporting, lysosomal V0 subunit D2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP6V0D2 mRNA

NCBI chr 4:19,876,838...19,922,566
Ensembl chr 4:19,876,841...19,922,605

G

ATPase, H+ transporting, lysosomal V1 subunit E2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP6V1E2 mRNA

NCBI chr17:87,251,537...87,255,315
Ensembl chr17:87,251,537...87,255,325

G

ATPase, H+ transporting, lysosomal V1 subunit F

increases expression
multiple interactions
decreases expression

Dextran Sulfate results in increased expression of ATP6V1F mRNA
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of ATP6V1F protein]

PMID:35093514 PMID:35362542

NCBI chr 6:29,467,782...29,470,508
Ensembl chr 6:29,467,717...29,470,511

G

ATPase, H+ transporting, lysosomal V1 subunit G3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP6V1G3 mRNA

NCBI chr 1:138,201,476...138,217,200
Ensembl chr 1:138,201,476...138,217,200

G

ATPase, copper transporting, alpha polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP7A mRNA

NCBI chr X:105,070,830...105,171,766
Ensembl chr X:105,070,882...105,168,532

G

ATPase, class I, type 8B, member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP8B1 mRNA

NCBI chr18:64,662,050...64,794,342
Ensembl chr18:64,662,038...64,794,338

G

ATPase, class I, type 8B, member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP8B2 mRNA

NCBI chr 3:89,846,795...89,870,645
Ensembl chr 3:89,846,788...89,870,815

G

arginine vasopressin receptor 1A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AVPR1A mRNA

NCBI chr10:122,284,404...122,289,358
Ensembl chr10:122,284,404...122,289,357

G

arginine vasopressin receptor 1B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AVPR1B mRNA

NCBI chr 1:131,526,908...131,539,740
Ensembl chr 1:131,526,977...131,539,738

G

arginine vasopressin receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AVPR2 mRNA

NCBI chr X:72,935,371...72,938,034
Ensembl chr X:72,935,708...72,939,108

G

axin 2

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 mRNA; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 protein; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 mRNA]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 protein]

NCBI chr11:108,808,687...108,841,609
Ensembl chr11:108,811,175...108,841,609

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of B3GNT3 mRNA

NCBI chr 8:72,144,017...72,155,270
Ensembl chr 8:72,143,400...72,154,433

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7

decreases expression
increases expression
multiple interactions

Dextran Sulfate results in decreased expression of B3GNT7 protein
Dextran Sulfate results in increased expression of B3GNT7 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of B3GNT7 protein]; evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of B3GNT7 protein]

PMID:32272095 PMID:35362542

NCBI chr 1:86,230,943...86,235,027
Ensembl chr 1:86,230,554...86,235,027

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of B3GNT8 mRNA

NCBI chr 7:25,327,025...25,328,917
Ensembl chr 7:25,326,079...25,334,525

G

bile acid-Coenzyme A: amino acid N-acyltransferase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BAAT mRNA

NCBI chr 4:49,489,416...49,507,915
Ensembl chr 4:49,489,422...49,506,557

G

BAF nuclear assembly factor 1

multiple interactions
increases expression
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of BANF1 protein]; evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of BANF1 protein]

PMID:32272095 PMID:35362542

NCBI chr19:5,414,661...5,416,904
Ensembl chr19:5,414,666...5,417,196

G

B cell scaffold protein with ankyrin repeats 1

increases expression

Dextran Sulfate results in increased expression of BANK1 mRNA

NCBI chr 3:135,759,124...136,031,902
Ensembl chr 3:135,759,124...136,031,827

G

BCL2-associated X protein

multiple interactions
increases expression

[RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased expression of BAX mRNA; [RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased expression of BAX protein; daphnetin inhibits the reaction [Dextran Sulfate results in increased expression of BAX protein]; flavokawain B inhibits the reaction [Dextran Sulfate results in increased cleavage of BAX protein]; flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of BAX protein]

PMID:24146755 PMID:37209277 PMID:38583725

NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322

G

butyrylcholinesterase

multiple interactions
decreases activity

[Chlorpyrifos co-treated with Dextran Sulfate] results in decreased activity of BCHE protein
Dextran Sulfate results in decreased activity of BCHE protein

PMID:31226429 PMID:31807802

NCBI chr 3:73,543,138...73,615,767
Ensembl chr 3:73,543,141...73,615,748

G

B cell leukemia/lymphoma 2

multiple interactions
decreases expression

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein]; daphnetin inhibits the reaction [Dextran Sulfate results in decreased expression of BCL2 protein]; flavokawain B inhibits the reaction [Dextran Sulfate results in decreased expression of BCL2 protein]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein]

PMID:25449198 PMID:37209277 PMID:38583725

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

G

B cell leukemia/lymphoma 6

multiple interactions

BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of and results in decreased secretion of IL10 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL1B protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL6 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of TNF protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased phosphorylation of JAK2 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased phosphorylation of STAT3 protein]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of and results in decreased secretion of IL10 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL1B protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL6 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of TNF protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]]

NCBI chr16:23,780,058...23,807,602
Ensembl chr16:23,783,802...23,807,602

G

B cell CLL/lymphoma 7C

increases expression

Dextran Sulfate results in increased expression of BCL7C mRNA

NCBI chr 7:127,260,626...127,307,938
Ensembl chr 7:127,260,628...127,308,105

G

bradykinin receptor, beta 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BDKRB1 mRNA

NCBI chr12:105,570,350...105,571,770
Ensembl chr12:105,569,344...105,571,687

G

bradykinin receptor, beta 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BDKRB2 mRNA

NCBI chr12:105,529,431...105,561,503
Ensembl chr12:105,529,485...105,561,496

G

beclin 1, autophagy related

multiple interactions
increases expression

2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in increased expression of BECN1 protein]; [Dextran Sulfate co-treated with 6-formylindolo(3,2-b)carbazole] results in increased expression of BECN1 protein; [Dextran Sulfate co-treated with alpinetin] results in increased expression of BECN1 protein; [Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein; [HU 308 co-treated with Dextran Sulfate] affects the expression of BECN1 protein; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein]; HU 308 promotes the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein]; Leucine inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in increased expression of BECN1 protein]; Nicotine promotes the reaction [Dextran Sulfate results in increased expression of BECN1 protein]
dorsomorphin inhibits the reaction [Nicotine promotes the reaction [Dextran Sulfate results in increased expression of BECN1 protein]]; Nicotine promotes the reaction [Dextran Sulfate results in increased expression of BECN1 protein]

PMID:27611972 PMID:31676321 PMID:31926917

NCBI chr11:101,179,084...101,193,112
Ensembl chr11:101,176,778...101,193,112

G

bestrophin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BEST1 mRNA

NCBI chr19:9,962,536...9,978,997
Ensembl chr19:9,962,538...9,978,997

G

biglycan

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BGN mRNA

NCBI chr X:72,527,207...72,539,542
Ensembl chr X:72,527,208...72,539,539

G

bridging integrator 2

decreases expression

Dextran Sulfate results in decreased expression of BIN2 protein

NCBI chr15:100,538,963...100,567,384
Ensembl chr15:100,538,958...100,567,434

G

baculoviral IAP repeat-containing 5

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein]

NCBI chr11:117,740,063...117,746,569
Ensembl chr11:117,740,077...117,746,569

G

baculoviral IAP repeat-containing 6

decreases expression

Dextran Sulfate results in decreased expression of BIRC6 mRNA

NCBI chr17:74,835,247...75,010,351
Ensembl chr17:74,835,290...75,010,351

G

bone morphogenetic protein 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMP1 mRNA

NCBI chr14:70,711,998...70,758,280
Ensembl chr14:70,711,998...70,757,674

G

bone morphogenetic protein 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMP10 mRNA

NCBI chr 6:87,405,976...87,411,494
Ensembl chr 6:87,405,976...87,414,659

G

bone morphogenetic protein 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMP7 mRNA

NCBI chr 2:172,709,805...172,782,114
Ensembl chr 2:172,709,805...172,782,114

G

bone morphogenetic protein receptor, type 1B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMPR1B mRNA

NCBI chr 3:141,540,230...141,875,335
Ensembl chr 3:141,542,897...141,875,186

G

bone morphogenetic protein receptor type 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BMPR2 mRNA

NCBI chr 1:59,802,721...59,917,240
Ensembl chr 1:59,802,559...59,918,173

G

BPI fold containing family A, member 1

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of BPIFA1 protein

NCBI chr 2:153,984,800...153,991,137
Ensembl chr 2:153,984,800...153,991,139

G

3'(2'), 5'-bisphosphate nucleotidase 2

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of BPNT2 protein
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of BPNT2 protein]

NCBI chr 4:4,762,484...4,793,306
Ensembl chr 4:4,762,484...4,793,355

G

BRICK1, SCAR/WAVE actin-nucleating complex subunit

multiple interactions
increases expression

evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of BRK1 protein]

NCBI chr 6:113,581,733...113,593,912
Ensembl chr 6:113,581,733...113,593,912

G

B-box and SPRY domain containing

increases expression

Dextran Sulfate results in increased expression of BSPRY mRNA

NCBI chr 4:62,398,248...62,415,537
Ensembl chr 4:62,398,290...62,415,535

G

bone marrow stromal cell antigen 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BST1 mRNA

NCBI chr 5:43,976,235...44,000,810
Ensembl chr 5:43,976,227...44,001,328

G

basic transcription factor 3-like 4

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of BTF3L4 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of BTF3L4 protein]

NCBI chr 4:108,671,489...108,691,445
Ensembl chr 4:108,671,492...108,690,811

G

core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase, 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of C1GALT1 mRNA

NCBI chr 6:7,845,224...7,872,042
Ensembl chr 6:7,844,842...7,875,687

G

C1GALT1-specific chaperone 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of C1GALT1C1 mRNA

NCBI chr X:37,719,660...37,724,020
Ensembl chr X:37,719,662...37,723,964

G

complement component 1, q subcomponent, alpha polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C1QA mRNA

NCBI chr 4:136,623,227...136,626,155
Ensembl chr 4:136,623,228...136,626,114

G

complement component 1, q subcomponent, beta polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C1QB mRNA

NCBI chr 4:136,607,437...136,613,511
Ensembl chr 4:136,607,440...136,613,498

G

C1q and tumor necrosis factor related protein 6

decreases expression

Dextran Sulfate results in decreased expression of C1QTNF6 mRNA

NCBI chr15:78,407,546...78,416,370
Ensembl chr15:78,407,546...78,415,616

G

complement component 1, r subcomponent A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C1RA mRNA

NCBI chr 6:124,489,580...124,500,399
Ensembl chr 6:124,489,364...124,500,402

G

complement component 1, s subcomponent 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C1S1 mRNA

NCBI chr 6:124,507,303...124,519,340
Ensembl chr 6:124,507,304...124,519,318

G

complement component 1, s subcomponent 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C1S2 mRNA

NCBI chr 6:124,601,584...124,613,044
Ensembl chr 6:124,601,584...124,613,044

G

complement component 3

multiple interactions
decreases expression

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of C3 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C3 mRNA; evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of C3 protein]

PMID:29950665 PMID:35362542 PMID:35999755

NCBI chr17:57,510,967...57,535,136
Ensembl chr17:57,510,970...57,535,136

G

complement component 3a receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C3AR1 mRNA

NCBI chr 6:122,824,099...122,833,116
Ensembl chr 6:122,824,097...122,833,120

G

complement C4B (Chido blood group)

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C4B mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of C4B protein]

PMID:29950665 PMID:32272095

NCBI chr17:34,947,249...34,962,876
Ensembl chr17:34,947,354...34,962,856

G

complement component 4 binding protein

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of C4BP mRNA

NCBI chr 1:130,562,510...130,589,365
Ensembl chr 1:130,562,510...130,589,369

G

complement component 5a receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C5AR1 mRNA

NCBI chr 7:15,980,668...15,993,465
Ensembl chr 7:15,980,668...15,993,465

G

calcium binding protein 39

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CAB39 mRNA

NCBI chr 1:85,707,796...85,779,298
Ensembl chr 1:85,721,162...85,779,297

G

calcium channel, voltage-dependent, alpha 1F subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CACNA1F mRNA

NCBI chr X:7,473,342...7,501,435
Ensembl chr X:7,473,322...7,501,435

G

calcium channel, voltage-dependent, L type, alpha 1S subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CACNA1S mRNA

NCBI chr 1:135,980,549...136,047,268
Ensembl chr 1:135,980,488...136,047,560

G

calcitonin/calcitonin-related polypeptide, alpha

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CALCA mRNA

NCBI chr 7:114,225,223...114,236,145
Ensembl chr 7:114,230,713...114,235,592

G

calcitonin-related polypeptide, beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CALCB mRNA

NCBI chr 7:114,315,790...114,322,603
Ensembl chr 7:114,317,878...114,322,600

G

calmodulin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CALM1 mRNA

NCBI chr12:100,165,694...100,176,083
Ensembl chr12:100,165,694...100,176,073

G

calmodulin 2

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CALM2 protein
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CALM2 protein

NCBI chr17:87,740,829...87,754,363
Ensembl chr17:87,740,840...87,754,363

G

calreticulin

decreases expression

Dextran Sulfate results in decreased expression of CALR protein

NCBI chr 8:85,568,717...85,573,560
Ensembl chr 8:85,568,479...85,573,563

G

calcium/calmodulin-dependent protein kinase II gamma

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CAMK2G mRNA

NCBI chr14:20,784,943...20,844,225
Ensembl chr14:20,784,943...20,844,156

G

calcium/calmodulin-dependent protein kinase IV

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CAMK4 mRNA

NCBI chr18:33,067,995...33,328,820
Ensembl chr18:33,067,984...33,324,281

G

calcium/calmodulin-dependent protein kinase kinase 1, alpha

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CAMKK1 mRNA

NCBI chr11:72,906,869...72,932,899
Ensembl chr11:72,909,834...72,932,899

G

cyclase associated actin cytoskeleton regulatory protein 1

decreases expression

Dextran Sulfate results in decreased expression of CAP1 protein

NCBI chr 4:122,752,841...122,779,869
Ensembl chr 4:122,752,840...122,779,849

G

calpain 13

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CAPN13 protein]

NCBI chr17:73,613,451...73,706,376
Ensembl chr17:73,613,459...73,707,861

G

capping actin protein of muscle Z-line subunit beta

decreases expression

Dextran Sulfate results in decreased expression of CAPZB protein

NCBI chr 4:138,920,210...139,019,131
Ensembl chr 4:138,920,210...139,019,129

G

carbonic anhydrase 1

multiple interactions
decreases expression

evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of CAR1 protein]

NCBI chr 3:14,831,274...14,873,425
Ensembl chr 3:14,831,276...14,873,428

G

carbonic anhydrase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CAR2 mRNA

NCBI chr 3:14,951,329...14,965,830
Ensembl chr 3:14,951,333...14,965,830

G

carbonic anhydrase 3

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CA3 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of CA3 protein]

NCBI chr 3:14,928,598...14,937,441
Ensembl chr 3:14,928,572...14,937,583

G

carbonic anhydrase 4

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CA4 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CA4 protein]

NCBI chr11:84,848,580...84,856,880
Ensembl chr11:84,848,612...84,856,870

G

calcium/calmodulin dependent serine protein kinase

multiple interactions
increases expression

evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of CASK protein]

NCBI chr X:13,383,319...13,713,020
Ensembl chr X:13,383,319...13,717,606

G

caspase 1

multiple interactions
increases expression

3-methyladenine affects the reaction [[HU 308 co-treated with Dextran Sulfate] affects the cleavage of CASP1 protein]; [Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of CASP1 mRNA; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of CASP1 protein; [HU 308 co-treated with Dextran Sulfate] affects the cleavage of CASP1 protein; [Streptozocin co-treated with Dextran Sulfate] results in increased cleavage of CASP1 protein; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]; Dextran Sulfate results in increased activity of and results in increased cleavage of CASP1 protein; dorsomorphin inhibits the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]]; HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased activity of and results in increased cleavage of CASP1 protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased activity of and results in increased cleavage of CASP1 protein]
celastrol inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide promotes the reaction [celastrol inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 protein]]
Dextran Sulfate results in increased expression of CASP1 mRNA; Dextran Sulfate results in increased expression of CASP1 protein

PMID:27611972 PMID:30270565 PMID:32470352 PMID:34964214 PMID:37001609

NCBI chr 9:5,298,517...5,307,281
Ensembl chr 9:5,298,508...5,307,290

G

caspase 3

increases cleavage
multiple interactions
increases activity

Dextran Sulfate results in increased cleavage of CASP3 protein
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CASP3 mRNA; alpinetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; biochanin A inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; daphnetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased activity of CASP3 protein]; gingerol inhibits the reaction [Dextran Sulfate results in increased activity of CASP3 protein]; Leucine inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]]; Plant Extracts inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased activity of CASP3 protein]

PMID:21989142 PMID:27920257 PMID:28421826 PMID:29950665 PMID:31676321 More...

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

caspase 8

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CASP8 protein
dihydrotanshinone I inhibits the reaction [Dextran Sulfate results in decreased expression of CASP8 protein]

NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662

G

catalase

decreases activity
increases activity
multiple interactions

Dextran Sulfate results in decreased activity of CAT protein
Dextran Sulfate results in increased activity of CAT protein
[Streptozocin co-treated with Dextran Sulfate] results in decreased expression of CAT protein; Fatty Acids, Omega-3 inhibits the reaction [Dextran Sulfate results in increased activity of CAT protein]; gingerol inhibits the reaction [Dextran Sulfate results in decreased activity of CAT protein]; mangiferin inhibits the reaction [Dextran Sulfate results in decreased activity of CAT protein]; Qingdai compound inhibits the reaction [Dextran Sulfate results in decreased activity of CAT protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in decreased activity of CAT protein]

PMID:27125760 PMID:28421826 PMID:30489199 PMID:31737179 PMID:34964214

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

G

caveolae associated 2

decreases expression

Dextran Sulfate results in decreased expression of CAVIN2 protein

NCBI chr 1:51,328,285...51,342,119
Ensembl chr 1:51,328,285...51,342,119

G

carbonyl reductase 1

decreases expression

Dextran Sulfate results in decreased expression of CBR1 protein

NCBI chr16:93,404,752...93,407,226
Ensembl chr16:93,402,741...93,407,393

G

carbonyl reductase 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CBR3 mRNA

NCBI chr16:93,480,107...93,487,879
Ensembl chr16:93,480,103...93,487,878

G

coiled-coil domain containing 12

increases expression

Dextran Sulfate results in increased expression of CCDC12 mRNA

NCBI chr 9:110,483,376...110,540,661
Ensembl chr 9:110,485,571...110,540,674

G

coiled-coil domain containing 124

increases expression

Dextran Sulfate results in increased expression of CCDC124 mRNA

NCBI chr 8:71,320,870...71,326,134
Ensembl chr 8:71,320,871...71,326,579

G

coiled-coil domain containing 13

increases expression

Dextran Sulfate results in increased expression of CCDC13 mRNA

NCBI chr 9:121,626,690...121,668,581
Ensembl chr 9:121,626,693...121,668,527

G

coiled-coil domain containing 158

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CCDC158 protein]

NCBI chr 5:92,756,096...92,823,327
Ensembl chr 5:92,755,813...92,823,130

G

coiled-coil domain containing 88B

increases expression

Dextran Sulfate results in increased expression of CCDC88B mRNA

NCBI chr19:6,821,991...6,835,586
Ensembl chr19:6,821,991...6,835,579

G

coiled-coil domain containing 9

increases expression

Dextran Sulfate results in increased expression of CCDC9 mRNA

NCBI chr 7:16,005,938...16,020,713
Ensembl chr 7:16,007,967...16,020,720

G

coiled-coil domain containing 96

increases expression

Dextran Sulfate results in increased expression of CCDC96 mRNA

NCBI chr 5:36,641,932...36,645,515
Ensembl chr 5:36,641,932...36,645,516

G

coiled-coil alpha-helical rod protein 1

increases expression

Dextran Sulfate results in increased expression of CCHCR1 mRNA

NCBI chr17:35,827,914...35,841,912
Ensembl chr17:35,827,997...35,841,912

G

cholecystokinin B receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CCKBR mRNA

NCBI chr 7:105,075,201...105,085,546
Ensembl chr 7:105,074,938...105,120,105

G

C-C motif chemokine ligand 11

increases secretion
increases expression
multiple interactions

Dextran Sulfate results in increased secretion of CCL11 protein
Dextran Sulfate results in increased expression of CCL11 mRNA
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL11 mRNA; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of CCL11 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased secretion of CCL11 protein]

PMID:21858153 PMID:29950665 PMID:32033881

NCBI chr11:81,948,658...81,953,781
Ensembl chr11:81,948,649...81,953,781

G

C-C motif chemokine ligand 2

increases secretion
increases expression
multiple interactions

Dextran Sulfate results in increased secretion of CCL2 protein
Dextran Sulfate results in increased expression of CCL2 mRNA
[RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased secretion of CCL2 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL2 mRNA; flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of CCL2 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased secretion of CCL2 protein]

PMID:19645018 PMID:20079348 PMID:21858153 PMID:24146755 PMID:29950665 More...

NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279

G

C-C motif chemokine ligand 21 (serine)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL21A mRNA

NCBI chr 4:42,772,860...42,773,991
Ensembl chr 4:42,772,860...42,773,993

G

C-C motif chemokine ligand 24

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL24 mRNA

NCBI chr 5:135,598,789...135,601,977
Ensembl chr 5:135,598,791...135,601,903

G

C-C motif chemokine ligand 25

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CCL25 mRNA

NCBI chr 8:4,375,207...4,410,020
Ensembl chr 8:4,375,210...4,410,020

G

C-C motif chemokine ligand 27A

increases expression

Dextran Sulfate results in increased expression of CCL27A mRNA

NCBI chr 4:41,769,467...41,774,251
Ensembl chr 4:41,769,467...41,774,247

G

C-C motif chemokine ligand 28

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CCL28 mRNA

NCBI chr13:120,085,355...120,115,895
Ensembl chr13:120,085,355...120,115,895

G

C-C motif chemokine ligand 3

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CCL3 mRNA
ligustilide inhibits the reaction [Dextran Sulfate results in increased expression of CCL3 mRNA]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of CCL3 mRNA]
Hesperidin inhibits the reaction [Dextran Sulfate results in increased expression of CCL3 protein]

PMID:19645018 PMID:30811821 PMID:33130971

NCBI chr11:83,538,669...83,540,204
Ensembl chr11:83,538,670...83,540,181

G

C-C motif chemokine ligand 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL4 mRNA

NCBI chr11:83,553,410...83,555,509
Ensembl chr11:83,553,410...83,555,509

G

C-C motif chemokine ligand 6

decreases expression
increases expression

Dextran Sulfate results in decreased expression of CCL6 mRNA
Dextran Sulfate results in increased expression of CCL6 mRNA

PMID:19645018 PMID:35093514

NCBI chr11:83,478,712...83,483,913
Ensembl chr11:83,478,708...83,483,913

G

C-C motif chemokine ligand 7

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CCL7 mRNA
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL7 mRNA; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of CCL7 mRNA]

PMID:19645018 PMID:29950665 PMID:32033881

NCBI chr11:81,936,538...81,938,351
Ensembl chr11:81,936,538...81,938,351

G

C-C motif chemokine ligand 8

increases expression

Dextran Sulfate results in increased expression of CCL8 mRNA

PMID:19645018 PMID:23894361

NCBI chr11:82,006,011...82,007,625
Ensembl chr11:82,006,011...82,007,625

G

C-C motif chemokine ligand 9

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL9 mRNA
Dextran Sulfate results in increased expression of CCL9 mRNA

PMID:29950665 PMID:35093514

NCBI chr11:83,463,743...83,469,462
Ensembl chr11:83,463,745...83,469,462

G

cyclin D1

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 mRNA; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 protein; [Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of CCND1 protein; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 mRNA]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 protein]; obeticholic acid inhibits the reaction [[Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of CCND1 protein]

PMID:31715269 PMID:35439472

NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662

G

C-C motif chemokine receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR2 mRNA

NCBI chr 9:123,901,954...123,913,594
Ensembl chr 9:123,901,987...123,913,594

G

C-C motif chemokine receptor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR4 mRNA

NCBI chr 9:114,319,384...114,334,544
Ensembl chr 9:114,319,384...114,333,984

G

C-C motif chemokine receptor 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR5 mRNA

NCBI chr 9:123,921,557...123,934,153
Ensembl chr 9:123,921,580...123,947,736

G

C-C motif chemokine receptor 7

multiple interactions

Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of CCR7 mRNA]; Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of CCR7 protein]

NCBI chr11:99,035,025...99,045,903
Ensembl chr11:99,035,022...99,045,903

G

C-C motif chemokine receptor 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR8 mRNA

NCBI chr 9:119,921,199...119,923,972
Ensembl chr 9:119,921,180...119,923,972

G

C-C motif chemokine receptor-like 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCRL2 mRNA

NCBI chr 9:110,883,902...110,886,586
Ensembl chr 9:110,883,554...110,886,587

G

centriole, cilia and spindle associated protein

increases expression

Dextran Sulfate results in increased expression of CCSAP mRNA

NCBI chr 8:124,566,712...124,586,948
Ensembl chr 8:124,567,570...124,586,948

G

CD14 antigen

multiple interactions
affects response to substance

[Dextran Sulfate affects the susceptibility to CD14 protein] which affects the expression of IFNG mRNA; CD14 protein inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]

NCBI chr18:36,858,117...36,859,868
Ensembl chr18:36,858,120...36,859,851

G

CD163 antigen

increases expression

Dextran Sulfate results in increased expression of CD163 mRNA

NCBI chr 6:124,281,596...124,307,488
Ensembl chr 6:124,281,615...124,307,486

G

CD177 antigen

increases expression

Dextran Sulfate results in increased expression of CD177 mRNA

NCBI chr 7:24,443,408...24,459,759
Ensembl chr 7:24,443,408...24,459,736

G

CD180 antigen

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CD180 mRNA
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD180 mRNA

PMID:23894361 PMID:29950665

NCBI chr13:102,830,055...102,843,139
Ensembl chr13:102,830,066...102,876,137

G

CD19 antigen

increases expression

Dextran Sulfate results in increased expression of CD19 mRNA

NCBI chr 7:126,007,620...126,016,401
Ensembl chr 7:126,007,622...126,014,061

G

CD200 molecule

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD200 mRNA

NCBI chr16:45,202,474...45,229,419
Ensembl chr16:45,202,498...45,229,416

G

CD209f antigen

decreases expression

Dextran Sulfate results in decreased expression of CD209F mRNA

NCBI chr 8:4,152,784...4,155,838
Ensembl chr 8:4,152,787...4,155,835

G

CD247 antigen

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD247 mRNA

NCBI chr 1:165,607,514...165,698,722
Ensembl chr 1:165,616,250...165,704,846

G

CD274 antigen

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD274 mRNA

NCBI chr19:29,339,428...29,365,495
Ensembl chr19:29,344,855...29,365,495

G

CD28 antigen

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD28 mRNA

NCBI chr 1:60,785,547...60,812,521
Ensembl chr 1:60,755,959...60,812,518

G

CD34 antigen

decreases expression

Dextran Sulfate results in decreased expression of CD34 mRNA

NCBI chr 1:194,621,239...194,643,587
Ensembl chr 1:194,621,127...194,643,587

G

CD4 antigen

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD4 mRNA

NCBI chr 6:124,841,656...124,865,210
Ensembl chr 6:124,841,655...124,865,184

G

CD44 antigen

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of CD44 mRNA

NCBI chr 2:102,641,486...102,732,014
Ensembl chr 2:102,641,486...102,732,010

G

CD52 antigen

increases expression

Dextran Sulfate results in increased expression of CD52 mRNA

NCBI chr 4:133,820,849...133,822,384
Ensembl chr 4:133,809,759...133,822,393

G

CD53 antigen

increases expression

Dextran Sulfate results in increased expression of CD53 mRNA

NCBI chr 3:106,666,177...106,697,465
Ensembl chr 3:106,667,237...106,697,465

G

CD55 molecule, decay accelerating factor for complement

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD55 mRNA

NCBI chr 1:130,357,526...130,390,513
Ensembl chr 1:130,366,764...130,390,481

G

CD55 molecule, decay accelerating factor for complement B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD55B mRNA

NCBI chr 1:130,316,263...130,350,831
Ensembl chr 1:130,316,274...130,350,746

G

CD68 antigen

increases expression
decreases expression
multiple interactions

dextran sulfate increases expression of CD68 protein in colonic lamina propria of mice
Dextran Sulfate results in decreased expression of CD68 protein
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of CD68 protein]

CTD
RGD

PMID:35362542 PMID:25004394

NCBI chr11:69,555,039...69,556,996
Ensembl chr11:69,555,039...69,556,979

G

CD72 antigen

increases expression

Dextran Sulfate results in increased expression of CD72 mRNA

NCBI chr 4:43,447,724...43,454,708
Ensembl chr 4:43,446,462...43,454,628

G

CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated)

increases expression
multiple interactions
decreases expression

Dextran Sulfate results in increased expression of CD74 mRNA
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of CD74 protein]
Dextran Sulfate results in decreased expression of CD74 mRNA; Dextran Sulfate results in decreased expression of CD74 protein

PMID:23894361 PMID:35093514 PMID:35362542

NCBI chr18:60,936,921...60,945,724
Ensembl chr18:60,936,920...60,945,724

G

CD79A antigen (immunoglobulin-associated alpha)

increases expression

Dextran Sulfate results in increased expression of CD79A mRNA

NCBI chr 7:24,596,922...24,601,283
Ensembl chr 7:24,596,806...24,601,622

G

CD79B antigen

increases expression

Dextran Sulfate results in increased expression of CD79B mRNA

NCBI chr11:106,202,167...106,205,388
Ensembl chr11:106,202,167...106,205,588

G

CD81 antigen

decreases expression

Dextran Sulfate results in decreased expression of CD81 mRNA

NCBI chr 7:142,606,487...142,621,667
Ensembl chr 7:142,606,476...142,621,671

G

CD86 antigen

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD86 mRNA; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 protein]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 protein]]; IRF4 protein promotes the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]; IRF4 protein promotes the reaction [Dextran Sulfate results in increased expression of CD86 protein]
Dextran Sulfate results in increased expression of CD86 mRNA; Dextran Sulfate results in increased expression of CD86 protein

PMID:29950665 PMID:38164749

NCBI chr16:36,389,318...36,486,439
Ensembl chr16:36,424,231...36,486,443

G

cytidine deaminase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CDA mRNA

NCBI chr 4:138,065,839...138,095,623
Ensembl chr 4:138,065,735...138,095,303

G

cadherin 1

multiple interactions
decreases expression

7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in decreased expression of CDH1 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CDH1 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CDH1 mRNA
Dextran Sulfate results in decreased expression of CDH1 mRNA; Dextran Sulfate results in decreased expression of CDH1 protein

PMID:29950665 PMID:34273909 PMID:36543318 PMID:37385329

NCBI chr 8:107,329,982...107,396,879
Ensembl chr 8:107,329,983...107,396,878

G

cadherin 2

multiple interactions
increases expression

7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased expression of CDH2 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CDH2 protein

PMID:34273909 PMID:36543318

NCBI chr18:16,721,934...16,942,303
Ensembl chr18:16,721,934...16,942,303

G

cadherin 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CDH5 mRNA

NCBI chr 8:104,828,247...104,871,136
Ensembl chr 8:104,828,257...104,871,143

G

cadherin-related family member 2

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CDHR2 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CDHR2 protein]

NCBI chr13:54,849,276...54,884,475
Ensembl chr13:54,849,274...54,884,475

G

cyclin dependent kinase 11B

increases expression

Dextran Sulfate results in increased expression of CDK11B mRNA

NCBI chr 4:155,709,303...155,734,392
Ensembl chr 4:155,709,311...155,734,395

G

cyclin dependent kinase inhibitor 1C

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CDKN1C mRNA

NCBI chr 7:143,012,076...143,014,735
Ensembl chr 7:143,012,076...143,014,787

G

CDP-diacylglycerol synthase 2

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CDS2 protein
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of CDS2 protein]

NCBI chr 2:132,105,068...132,153,970
Ensembl chr 2:132,105,068...132,153,970

G

caudal type homeobox 2

multiple interactions
decreases expression
increases expression

6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased expression of CDX2 protein]; nitazoxanide inhibits the reaction [Dextran Sulfate results in decreased expression of CDX2 protein]

PMID:29680209 PMID:38663798

NCBI chr 5:147,237,710...147,244,059
Ensembl chr 5:147,237,615...147,244,080

G

CEA cell adhesion molecule 12

increases expression

Dextran Sulfate results in increased expression of CEACAM12 mRNA

NCBI chr 7:17,799,854...17,811,911
Ensembl chr 7:17,799,854...17,811,911

G

CCAAT/enhancer binding protein delta

increases expression

Dextran Sulfate results in increased expression of CEBPD mRNA

NCBI chr16:15,705,150...15,707,409
Ensembl chr16:15,705,150...15,708,895

G

carboxyl ester lipase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CEL mRNA

NCBI chr 2:28,445,831...28,453,415
Ensembl chr 2:28,445,807...28,453,415

G

centrosomal protein 131

increases expression

Dextran Sulfate results in increased expression of CEP131 mRNA

NCBI chr11:119,955,247...119,977,684
Ensembl chr11:119,955,256...119,977,653

G

carboxylesterase 1D

multiple interactions
decreases expression

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CES1D protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CES1D mRNA
Dextran Sulfate results in decreased expression of CES1D mRNA

PMID:29950665 PMID:35093514 PMID:35999755

NCBI chr 8:93,892,700...93,924,432
Ensembl chr 8:93,892,696...93,924,466

G

carboxylesterase 1E

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CES1E mRNA

NCBI chr 8:93,927,846...93,956,233
Ensembl chr 8:93,927,846...93,956,247

G

carboxylesterase 2A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CES2A mRNA

NCBI chr 8:105,460,635...105,468,266
Ensembl chr 8:105,460,635...105,468,266

G

carboxylesterase 2C

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CES2C mRNA

NCBI chr 8:105,573,700...105,581,115
Ensembl chr 8:105,573,700...105,581,115

G

carboxylesterase 2E

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CES2E mRNA

NCBI chr 8:105,652,892...105,661,304
Ensembl chr 8:105,652,892...105,661,304

G

carboxylesterase 2G

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CES2G mRNA

NCBI chr 8:105,688,350...105,696,169
Ensembl chr 8:105,688,350...105,696,169

G

cilia and flagella associated protein 45

increases expression

Dextran Sulfate results in increased expression of CFAP45 mRNA

NCBI chr 1:172,348,697...172,373,437
Ensembl chr 1:172,348,368...172,373,437

G

complement factor B

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of CFB protein

NCBI chr17:35,075,350...35,081,492
Ensembl chr17:35,075,350...35,081,494

G

complement factor D

increases expression

Dextran Sulfate results in increased expression of CFD protein

NCBI chr10:79,726,687...79,728,489
Ensembl chr10:79,726,687...79,728,489

G

complement component factor h

multiple interactions
increases expression

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of CFH protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CFH mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of CFH protein]
Dextran Sulfate results in increased expression of CFH mRNA; Dextran Sulfate results in increased expression of CFH protein

PMID:29950665 PMID:32272095 PMID:35093514 PMID:35999755

NCBI chr 1:140,013,593...140,111,149
Ensembl chr 1:140,012,446...140,111,502

G

cofilin 1, non-muscle

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CFL1 protein
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CFL1 protein

NCBI chr19:5,540,483...5,544,059
Ensembl chr19:5,540,483...5,545,229

G

CASP8 and FADD-like apoptosis regulator

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein]

NCBI chr 1:58,750,353...58,798,043
Ensembl chr 1:58,750,667...58,798,043

G

cystic fibrosis transmembrane conductance regulator

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFTR mRNA

NCBI chr 6:18,170,686...18,322,769
Ensembl chr 6:18,170,686...18,322,767

G

cell growth regulator with EF hand domain 1

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of CGREF1 protein

NCBI chr 5:31,090,487...31,102,771
Ensembl chr 5:31,090,487...31,102,935

G

chromatin assembly factor 1, subunit A

increases expression

Dextran Sulfate results in increased expression of CHAF1A mRNA

NCBI chr17:56,347,404...56,375,027
Ensembl chr17:56,347,439...56,379,289

G

calcium homeostasis endoplasmic reticulum protein

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CHERP protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CHERP protein]

NCBI chr 8:73,214,327...73,229,077
Ensembl chr 8:73,214,333...73,229,070

G

chromogranin A

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CHGA protein
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of CHGA protein]

NCBI chr12:102,521,200...102,531,286
Ensembl chr12:102,521,228...102,531,287

G

chitinase-like 3

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CHIL3 mRNA; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CHIL3 mRNA]

NCBI chr 3:106,054,870...106,074,852
Ensembl chr 3:106,054,870...106,074,880

G

charged multivesicular body protein 2A

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CHMP2A protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CHMP2A protein]

NCBI chr 7:12,765,933...12,768,704
Ensembl chr 7:12,765,937...12,768,734

G

charged multivesicular body protein 4B

increases expression

Dextran Sulfate results in increased expression of CHMP4B mRNA

NCBI chr 2:154,498,949...154,536,703
Ensembl chr 2:154,493,625...154,536,705

G

chimerin 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CHN2 mRNA

NCBI chr 6:54,016,917...54,278,797
Ensembl chr 6:54,016,539...54,278,795

G

cysteine and histidine rich domain containing 1

multiple interactions
increases expression

evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of CHORDC1 protein]

NCBI chr 9:18,203,563...18,225,296
Ensembl chr 9:18,203,421...18,228,738

G

calcineurin-like EF hand protein 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CHP1 protein
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of CHP1 protein]

NCBI chr 2:119,378,172...119,417,505
Ensembl chr 2:119,378,178...119,417,508

G

chordin-like 2

increases expression

Dextran Sulfate results in increased expression of CHRDL2 mRNA

NCBI chr 7:99,655,611...99,683,935
Ensembl chr 7:99,655,379...99,683,935

G

cholinergic receptor, muscarinic 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CHRM4 mRNA

NCBI chr 2:91,752,531...91,760,180
Ensembl chr 2:91,757,594...91,759,033

G

cholinergic receptor nicotinic alpha 2 subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHRNA2 mRNA

NCBI chr14:66,370,685...66,390,397
Ensembl chr14:66,372,488...66,390,397

G

cholinergic receptor, nicotinic, alpha polypeptide 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHRNA7 mRNA

NCBI chr 7:62,748,440...62,862,274
Ensembl chr 7:62,748,440...62,862,317

G

cholinergic receptor, nicotinic, beta polypeptide 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CHRNB3 mRNA

NCBI chr 8:27,858,688...27,889,758
Ensembl chr 8:27,858,739...27,889,758

G

cholinergic receptor, nicotinic, epsilon polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHRNE mRNA

NCBI chr11:70,505,709...70,510,074
Ensembl chr11:70,505,709...70,510,042

G

carbohydrate sulfotransferase 11

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHST11 mRNA

NCBI chr10:82,820,274...83,031,738
Ensembl chr10:82,821,332...83,031,734

G

conserved helix-loop-helix ubiquitous kinase

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CHUK protein modified form
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of CHUK protein modified form]

NCBI chr19:44,061,773...44,095,940
Ensembl chr19:44,061,774...44,095,919

G

CDGSH iron sulfur domain 1

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CISD1 protein
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of CISD1 protein]

NCBI chr10:71,166,324...71,180,679
Ensembl chr10:71,166,310...71,180,784

G

creatine kinase, brain

decreases expression

Dextran Sulfate results in decreased expression of CKB protein

NCBI chr12:111,635,789...111,638,772
Ensembl chr12:111,635,795...111,638,772

G

creatine kinase, muscle

decreases expression

Dextran Sulfate results in decreased expression of CKM protein

NCBI chr 7:19,145,019...19,155,508
Ensembl chr 7:19,138,701...19,156,766

G

chloride channel accessory 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CLCA1 mRNA

NCBI chr 3:144,710,298...144,738,537
Ensembl chr 3:144,709,578...144,738,537

G

chloride channel accessory 4A

increases expression

Dextran Sulfate results in increased expression of CLCA4 mRNA

NCBI chr 3:144,658,247...144,680,806
Ensembl chr 3:144,658,241...144,680,806

G

chloride channel, voltage-sensitive 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CLCN2 mRNA

NCBI chr16:20,521,185...20,536,496
Ensembl chr16:20,521,714...20,536,496

G

chloride channel, voltage-sensitive 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CLCN3 mRNA

NCBI chr 8:61,363,423...61,436,351
Ensembl chr 8:61,363,423...61,436,334

G

claudin 1

decreases expression
increases expression
multiple interactions

Dextran Sulfate results in decreased expression of CLDN1 mRNA; Dextran Sulfate results in decreased expression of CLDN1 protein
Dextran Sulfate results in increased expression of CLDN1 protein
7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased expression of CLDN1 protein]; [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone co-treated with Dextran Sulfate] results in decreased expression of CLDN1 protein; [SB 203580 co-treated with Dextran Sulfate] results in decreased expression of CLDN1 protein; biochanin A inhibits the reaction [Dextran Sulfate results in decreased expression of CLDN1 protein]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in decreased expression of CLDN1 protein]; isomaltulose inhibits the reaction [Dextran Sulfate results in decreased expression of CLDN1 mRNA]

PMID:27920472 PMID:35894244 PMID:36543318 PMID:37001609 PMID:38648921

NCBI chr16:26,175,395...26,190,589
Ensembl chr16:26,175,392...26,190,591

G

claudin 11

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CLDN11 mRNA

NCBI chr 3:31,204,069...31,218,475
Ensembl chr 3:31,204,069...31,218,473

G

claudin 2

multiple interactions
increases expression

6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased expression of CLDN2 mRNA]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased expression of CLDN2 protein]; 7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased expression of CLDN2 protein]; [Benzo(a)pyrene co-treated with Dextran Sulfate] results in decreased expression of CLDN2 mRNA
Dextran Sulfate results in increased expression of CLDN2 mRNA; Dextran Sulfate results in increased expression of CLDN2 protein

PMID:26271895 PMID:29680209 PMID:36543318

NCBI chr X:138,701,552...138,712,135
Ensembl chr X:138,701,577...138,712,135

G

C-type lectin domain family 10, member A

increases expression

Dextran Sulfate results in increased expression of CLEC10A mRNA

NCBI chr11:70,057,449...70,061,662
Ensembl chr11:70,047,023...70,061,660

G

chloride intracellular channel 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CLIC1 protein
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CLIC1 protein

NCBI chr17:35,269,219...35,277,695
Ensembl chr17:35,268,942...35,277,725

G

caseinolytic mitochondrial matrix peptidase proteolytic subunit

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CLPP protein
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of CLPP protein]

NCBI chr17:57,297,264...57,303,371
Ensembl chr17:57,297,305...57,303,188

G

chymase 1, mast cell

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CMA1 mRNA

NCBI chr14:56,178,908...56,182,132
Ensembl chr14:56,178,908...56,182,132

G

cytidine monophospho-N-acetylneuraminic acid synthetase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CMAS mRNA

NCBI chr 6:142,702,468...142,721,440
Ensembl chr 6:142,702,412...142,721,440

G

cytidine/uridine monophosphate kinase 1

decreases expression

Dextran Sulfate results in decreased expression of CMPK1 protein

NCBI chr 4:114,817,810...114,844,425
Ensembl chr 4:114,816,533...114,844,438

G

cyclic nucleotide gated channel alpha 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CNGA4 mRNA

NCBI chr 7:105,049,247...105,057,981
Ensembl chr 7:105,053,775...105,057,949

G

calponin 2

decreases expression

Dextran Sulfate results in decreased expression of CNN2 protein

NCBI chr10:79,824,434...79,831,234
Ensembl chr10:79,824,418...79,831,896

G

cannabinoid receptor 1

decreases response to substance
multiple interactions
increases expression

CNR1 results in decreased susceptibility to Dextran Sulfate
SB 203580 inhibits the reaction [Dextran Sulfate results in increased expression of CNR1 protein]; Serotonin inhibits the reaction [Dextran Sulfate results in increased expression of CNR1 protein]

PMID:15085199 PMID:27920472 PMID:30611738

NCBI chr 4:33,923,171...33,948,831
Ensembl chr 4:33,924,593...33,948,831

G

cannabinoid receptor 2

multiple interactions
increases response to substance
affects response to substance
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CNR2 mRNA; CNR2 gene mutant form promotes the reaction [Dextran Sulfate results in increased secretion of MPO protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in decreased expression of SQSTM1 protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of and results in increased secretion of IL1B protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of IL1B mRNA]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of NLRP3 protein]; CNR2 protein affects the reaction [Dextran Sulfate results in decreased phosphorylation of MTOR protein]; CNR2 protein affects the reaction [Dextran Sulfate results in decreased phosphorylation of RPS6KB1 protein]; CNR2 protein affects the susceptibility to [Azoxymethane co-treated with Dextran Sulfate]; SB 203580 inhibits the reaction [Dextran Sulfate results in increased expression of CNR2 protein]
CNR2 gene mutant form results in increased susceptibility to Dextran Sulfate
CNR2 protein affects the susceptibility to Dextran Sulfate

PMID:27611972 PMID:27920472 PMID:29950665 PMID:30102254 PMID:32942172

NCBI chr 4:135,622,500...135,647,530
Ensembl chr 4:135,622,705...135,647,518

G

ciliary neurotrophic factor receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CNTFR mRNA

NCBI chr 4:41,657,498...41,697,091
Ensembl chr 4:41,657,498...41,697,089

G

contactin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CNTN1 mRNA

NCBI chr15:91,949,034...92,239,834
Ensembl chr15:91,949,046...92,239,848

G

component of oligomeric golgi complex 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of COG1 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COG1 protein]

NCBI chr11:113,540,004...113,560,157
Ensembl chr11:113,539,995...113,557,880

G

collagen, type XI, alpha 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL11A1 mRNA

NCBI chr 3:113,823,933...114,014,405
Ensembl chr 3:113,824,189...114,014,367

G

collagen, type XIV, alpha 1

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL14A1 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of COL14A1 protein]

PMID:29950665 PMID:32272095

NCBI chr15:55,171,040...55,384,199
Ensembl chr15:55,171,146...55,384,199

G

collagen, type XVI, alpha 1

increases expression

Dextran Sulfate results in increased expression of COL16A1 mRNA

NCBI chr 4:129,941,638...129,993,070
Ensembl chr 4:129,941,633...129,993,076

G

collagen, type XVIII, alpha 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL18A1 mRNA

NCBI chr10:76,888,013...77,002,351
Ensembl chr10:76,888,012...77,002,382

G

collagen, type I, alpha 1

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL1A1 mRNA
Dextran Sulfate results in decreased expression of COL1A1 mRNA

PMID:29950665 PMID:35093514

NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868

G

collagen, type I, alpha 2

decreases expression

Dextran Sulfate results in decreased expression of COL1A2 mRNA

NCBI chr 6:4,505,618...4,541,543
Ensembl chr 6:4,504,814...4,541,544

G

collagen, type XXII, alpha 1

increases expression

Dextran Sulfate results in increased expression of COL22A1 mRNA

NCBI chr15:71,667,644...71,906,087
Ensembl chr15:71,667,644...71,906,076

G

collagen, type XXIII, alpha 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL23A1 mRNA

NCBI chr11:51,180,508...51,474,752
Ensembl chr11:51,180,747...51,474,745

G

collagen, type XXVIII, alpha 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL28A1 mRNA

NCBI chr 6:7,997,100...8,193,709
Ensembl chr 6:7,997,808...8,192,617

G

collagen, type III, alpha 1

decreases expression

Dextran Sulfate results in decreased expression of COL3A1 mRNA

NCBI chr 1:45,350,698...45,388,866
Ensembl chr 1:45,350,698...45,388,866

G

collagen, type IV, alpha 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL4A1 mRNA

NCBI chr 8:11,248,423...11,362,889
Ensembl chr 8:11,248,423...11,362,826

G

collagen, type IV, alpha 2

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL4A2 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COL4A2 protein]

PMID:29950665 PMID:32272095

NCBI chr 8:11,362,878...11,499,287
Ensembl chr 8:11,362,805...11,499,287

G

collagen, type V, alpha 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL5A1 mRNA

NCBI chr 2:27,776,393...27,929,522
Ensembl chr 2:27,776,437...27,929,526

G

collagen, type V, alpha 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL5A2 mRNA

NCBI chr 1:45,413,491...45,542,442
Ensembl chr 1:45,413,481...45,542,442

G

collagen, type VI, alpha 1

decreases expression
increases expression
multiple interactions

Dextran Sulfate results in decreased expression of COL6A1 mRNA; Dextran Sulfate results in decreased expression of COL6A1 protein
Dextran Sulfate results in increased expression of COL6A1 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COL6A1 protein]; evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of COL6A1 protein]

PMID:32272095 PMID:35093514 PMID:35362542

NCBI chr10:76,544,626...76,561,869
Ensembl chr10:76,544,626...76,562,002

G

collagen, type VI, alpha 2

decreases expression
increases expression
multiple interactions

Dextran Sulfate results in decreased expression of COL6A2 mRNA; Dextran Sulfate results in decreased expression of COL6A2 protein
Dextran Sulfate results in increased expression of COL6A2 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COL6A2 protein]; evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of COL6A2 protein]

PMID:32272095 PMID:35093514 PMID:35362542

NCBI chr10:76,431,590...76,459,464
Ensembl chr10:76,431,596...76,459,464

G

collagen, type VI, alpha 3

multiple interactions
increases expression

evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of COL6A3 protein]

NCBI chr 1:90,694,582...90,771,710
Ensembl chr 1:90,693,645...90,771,693

G

collagen, type VI, alpha 4

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of COL6A4 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COL6A4 protein]

NCBI chr 9:105,867,284...105,975,729
Ensembl chr 9:105,866,653...105,973,982

G

collagen, type VIII, alpha 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL8A1 mRNA

NCBI chr16:57,444,619...57,575,100
Ensembl chr16:57,444,621...57,575,100

G

collagen beta(1-O)galactosyltransferase 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of COLGALT1 protein
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of COLGALT1 protein]

NCBI chr 8:72,063,631...72,077,555
Ensembl chr 8:72,063,642...72,077,555

G

coatomer protein complex, subunit zeta 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of COPZ1 protein
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of COPZ1 protein]

NCBI chr15:103,181,261...103,208,295
Ensembl chr15:103,181,141...103,208,295

G

coenzyme Q6 monooxygenase

multiple interactions
increases expression

evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of COQ6 protein]

NCBI chr12:84,408,530...84,420,570
Ensembl chr12:84,408,431...84,420,570

G

coronin, actin binding protein 1A

decreases expression

Dextran Sulfate results in decreased expression of CORO1A protein

NCBI chr 7:126,298,946...126,303,925
Ensembl chr 7:126,298,945...126,306,959

G

coronin, actin binding protein 1C

decreases expression

Dextran Sulfate results in decreased expression of CORO1C protein

NCBI chr 5:113,980,500...114,046,767
Ensembl chr 5:113,980,497...114,046,819

G

coactosin like F-actin binding protein 1

decreases expression

Dextran Sulfate results in decreased expression of COTL1 protein

NCBI chr 8:120,535,953...120,567,318
Ensembl chr 8:120,535,961...120,567,283

G

cytochrome c oxidase assembly protein 17, copper chaperone

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of COX17 protein
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of COX17 protein]

NCBI chr16:38,167,332...38,173,125
Ensembl chr16:38,167,353...38,182,659

G

cytochrome c oxidase subunit 5B

increases expression

Dextran Sulfate results in increased expression of COX5B mRNA

NCBI chr 1:36,730,568...36,732,469
Ensembl chr 1:36,730,530...36,732,762

G

cytochrome c oxidase subunit 7A2

multiple interactions
decreases expression

evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of COX7A2 protein]

NCBI chr 9:79,662,523...79,667,135
Ensembl chr 9:79,662,643...79,667,160

G

ceruloplasmin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CP mRNA

NCBI chr 3:20,011,097...20,063,914
Ensembl chr 3:20,011,218...20,063,309

G

carboxypeptidase A1, pancreatic

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CPA1 mRNA

NCBI chr 6:30,639,217...30,645,360
Ensembl chr 6:30,639,217...30,645,362

G

carboxypeptidase B2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CPB2 mRNA

NCBI chr14:75,479,727...75,520,995
Ensembl chr14:75,479,727...75,520,995

G

copine I

multiple interactions
decreases expression

evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of CPNE1 protein]

NCBI chr 2:155,913,765...155,953,847
Ensembl chr 2:155,913,762...155,953,885

G

complement receptor 2

increases expression

Dextran Sulfate results in increased expression of CR2 mRNA

NCBI chr 1:194,819,120...194,859,096
Ensembl chr 1:194,819,119...194,859,024

G

capping protein inhibiting regulator of actin

increases expression

Dextran Sulfate results in increased expression of CRACD mRNA

NCBI chr 5:76,803,225...77,021,393
Ensembl chr 5:76,804,359...77,021,392

G

corticotropin releasing hormone receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CRHR1 mRNA

NCBI chr11:104,021,289...104,066,349
Ensembl chr11:104,023,681...104,066,349

G

corticotropin releasing hormone receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CRHR2 mRNA

NCBI chr 6:55,067,033...55,110,001
Ensembl chr 6:55,067,034...55,110,001

G

cysteine-rich secretory protein 4

decreases expression

Dextran Sulfate results in decreased expression of CRISP1 protein

NCBI chr 1:18,185,113...18,216,126
Ensembl chr 1:18,185,415...18,216,126

G

cartilage associated protein

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CRTAP mRNA

NCBI chr 9:114,204,204...114,219,743
Ensembl chr 9:114,204,202...114,219,743

G

colony stimulating factor 1 (macrophage)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CSF1 mRNA

NCBI chr 3:107,648,364...107,668,048
Ensembl chr 3:107,648,364...107,667,785

G

colony stimulating factor 2 (granulocyte-macrophage)

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CSF2 mRNA; Dextran Sulfate results in increased expression of CSF2 protein
[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [Dextran Sulfate results in increased expression of CSF2 protein]; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CSF2 mRNA; Polymyxin B inhibits the reaction [Dextran Sulfate results in increased expression of CSF2 protein]; Rutin inhibits the reaction [Dextran Sulfate results in increased expression of CSF2 mRNA]; TLR4 protein affects the reaction [Dextran Sulfate results in increased expression of CSF2 protein]

PMID:15652231 PMID:29950665 PMID:31442584

NCBI chr11:54,138,096...54,140,725
Ensembl chr11:54,138,097...54,140,493

G

colony stimulating factor 2 receptor, beta 2, low-affinity (granulocyte-macrophage)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CSF2RB2 mRNA

NCBI chr15:78,166,707...78,189,921
Ensembl chr15:78,166,707...78,189,921

G

colony stimulating factor 3 (granulocyte)

multiple interactions
increases expression

Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of CSF3 mRNA]

NCBI chr11:98,591,287...98,594,457
Ensembl chr11:98,592,089...98,594,455

G

colony stimulating factor 3 receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CSF3R mRNA

NCBI chr 4:125,917,241...125,938,233
Ensembl chr 4:125,918,343...125,938,233

G

casein kinase 1, alpha 1

multiple interactions
increases expression

evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of CSNK1A1 protein]

NCBI chr18:61,687,307...61,723,391
Ensembl chr18:61,688,345...61,723,132

G

cystathionine gamma lyase

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CTH protein
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of CTH protein]

NCBI chr 3:157,599,885...157,630,718
Ensembl chr 3:157,599,885...157,630,714

G

catenin beta 1

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CTNNB1 protein
[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate] results in increased expression of CTNNB1 protein; [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate] results in increased mutagenesis of CTNNB1 gene; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CTNNB1 protein; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CTNNB1 protein]; CTNNB1 gene mutant form results in increased susceptibility to [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate]

PMID:15459021 PMID:16049979 PMID:27664423 PMID:31715269

NCBI chr 9:120,762,466...120,789,573
Ensembl chr 9:120,758,282...120,789,573

G

cytidine 5'-triphosphate synthase 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CTPS1 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CTPS1 protein]

NCBI chr 4:120,397,065...120,427,473
Ensembl chr 4:120,397,065...120,427,473

G

cathepsin C

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CTSC mRNA; Dextran Sulfate results in decreased expression of CTSC protein
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of CTSC protein]

PMID:35093514 PMID:35362542

NCBI chr 7:87,927,233...87,960,083
Ensembl chr 7:87,927,293...87,960,096

G

cathepsin D

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of CTSD protein]

NCBI chr 7:141,929,647...141,941,564
Ensembl chr 7:141,929,648...141,941,775

G

cathepsin K

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CTSK mRNA

NCBI chr 3:95,406,521...95,416,698
Ensembl chr 3:95,406,567...95,416,673

G

cathepsin L

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CTSL protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CTSL mRNA

PMID:29950665 PMID:35999755

NCBI chr13:64,509,704...64,518,586
Ensembl chr13:64,507,151...64,518,704

G

cathepsin S

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CTSS protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CTSS protein]

NCBI chr 3:95,434,097...95,463,716
Ensembl chr 3:95,434,097...95,463,714

G

cubilin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CUBN mRNA

NCBI chr 2:13,281,149...13,496,687
Ensembl chr 2:13,281,149...13,496,624

G

C-X3-C motif chemokine receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CX3CR1 mRNA

NCBI chr 9:119,877,749...119,897,362
Ensembl chr 9:119,877,749...119,898,945

G

coxsackie virus and adenovirus receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CXADR mRNA

NCBI chr16:78,098,114...78,156,673
Ensembl chr16:78,098,377...78,156,662

G

C-X-C motif chemokine ligand 10

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL10 mRNA; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL10 mRNA]

NCBI chr 5:92,494,497...92,496,748
Ensembl chr 5:92,494,497...92,496,748

G

C-X-C motif chemokine ligand 12

decreases expression

Dextran Sulfate results in decreased expression of CXCL12 mRNA

NCBI chr 6:117,145,496...117,158,329
Ensembl chr 6:117,145,496...117,158,328

G

C-X-C motif chemokine ligand 13

increases expression

Dextran Sulfate results in increased expression of CXCL13 mRNA

PMID:23894361 PMID:35093514

NCBI chr 5:96,104,785...96,108,927
Ensembl chr 5:96,104,810...96,108,927

G

C-X-C motif chemokine ligand 14

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL14 mRNA

NCBI chr13:56,436,456...56,444,624
Ensembl chr13:56,436,456...56,444,364

G

C-X-C motif chemokine ligand 15

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CXCL15 protein; Dextran Sulfate results in increased expression of CXCL5 mRNA; Dextran Sulfate results in increased expression of CXCL8 protein
Dextran Sulfate results in increased expression of CXCL8 mRNA
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL5 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of CXCL8 protein]; evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of CXCL15 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of CXCL8 protein]

PMID:19645018 PMID:20637373 PMID:29950665 PMID:32272095 PMID:35362542 More...

NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926

G

C-X-C motif chemokine ligand 2

multiple interactions
increases expression

17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 protein]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of CXCL2 mRNA]; Benzo(a)pyrene inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 mRNA]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 mRNA]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 protein]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 protein]
Dextran Sulfate results in increased expression of CXCL2 mRNA; Dextran Sulfate results in increased expression of CXCL2 protein

PMID:21724996 PMID:32033881 PMID:34998820 PMID:36519841

NCBI chr 5:91,051,758...91,053,797
Ensembl chr 5:91,051,730...91,053,797

G

C-X-C motif chemokine ligand 3

multiple interactions
increases secretion
increases expression

17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CXCL1 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL1 mRNA; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of CXCL1 mRNA]; Benzo(a)pyrene inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 mRNA]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 protein]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased secretion of CXCL1 protein]
Dextran Sulfate results in increased expression of CXCL1 mRNA; Dextran Sulfate results in increased expression of CXCL1 protein

PMID:19645018 PMID:20079348 PMID:21724996 PMID:21858153 PMID:29950665 More...

NCBI chr 5:90,933,960...90,935,952
Ensembl chr 5:90,933,962...90,937,459

G

C-X-C motif chemokine ligand 9

increases expression

Dextran Sulfate results in increased expression of CXCL9 mRNA

NCBI chr 5:92,469,190...92,475,938
Ensembl chr 5:92,469,206...92,475,938

G

C-X-C motif chemokine receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCR2 mRNA

NCBI chr 1:74,193,153...74,200,405
Ensembl chr 1:74,193,150...74,200,405

G

cytochrome b-245, alpha polypeptide

increases expression

Dextran Sulfate results in increased expression of CYBA protein

NCBI chr 8:123,151,510...123,159,679
Ensembl chr 8:123,151,515...123,159,669

G

cytochrome b-245, beta polypeptide

increases expression

Dextran Sulfate results in increased expression of CYBB mRNA; Dextran Sulfate results in increased expression of CYBB protein

PMID:20637373 PMID:23894361

NCBI chr X:9,301,493...9,354,005
Ensembl chr X:9,301,491...9,354,010

G

cytoplasmic FMR1 interacting protein 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYFIP1 mRNA

NCBI chr 7:55,491,556...55,582,381
Ensembl chr 7:55,491,493...55,582,350

G

cytoplasmic FMR1 interacting protein 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYFIP2 mRNA

NCBI chr11:46,084,676...46,203,686
Ensembl chr11:46,084,677...46,203,686

G

cytoglobin

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CYGB protein
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of CYGB protein]

NCBI chr11:116,536,421...116,544,887
Ensembl chr11:116,536,421...116,545,139

G

cytochrome P450, family 11, subfamily a, polypeptide 1

decreases expression

Dextran Sulfate results in decreased expression of CYP11A1 mRNA

NCBI chr 9:57,905,307...57,934,314
Ensembl chr 9:57,913,694...57,934,306

G

cytochrome P450, family 17, subfamily a, polypeptide 1

decreases expression

Dextran Sulfate results in decreased expression of CYP17A1 mRNA

NCBI chr19:46,655,604...46,661,439
Ensembl chr19:46,655,604...46,661,611

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
decreases expression

6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in decreased expression of CYP1A1 mRNA]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in decreased expression of CYP1A1 protein]; Dextran Sulfate inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]
Dextran Sulfate results in decreased expression of CYP1A1 mRNA; Dextran Sulfate results in decreased expression of CYP1A1 protein

PMID:29680209 PMID:34998820

NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107

G

cytochrome P450, family 1, subfamily a, polypeptide 2

decreases activity
multiple interactions

Dextran Sulfate results in decreased activity of CYP1A2 protein
[Dextran Sulfate results in decreased activity of CYP1A2 protein] which results in decreased chemical synthesis of Acetaminophen

NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986

G

cytochrome P450, family 21, subfamily a, polypeptide 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP21A1 mRNA

NCBI chr17:35,020,322...35,023,400
Ensembl chr17:35,020,322...35,023,535

G

cytochrome P450, family 24, subfamily a, polypeptide 1

increases expression

Dextran Sulfate results in increased expression of CYP24A1 protein

NCBI chr 2:170,324,877...170,339,065
Ensembl chr 2:170,324,628...170,339,065

G

cytochrome P450, family 26, subfamily b, polypeptide 1

decreases expression

Dextran Sulfate results in decreased expression of CYP26B1 mRNA

NCBI chr 6:84,548,396...84,570,890
Ensembl chr 6:84,548,396...84,570,890

G

cytochrome P450, family 27, subfamily b, polypeptide 1

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP27B1 mRNA
Dextran Sulfate results in decreased expression of CYP27B1 protein

PMID:29950665 PMID:38588969

NCBI chr10:126,884,115...126,891,897
Ensembl chr10:126,884,119...126,888,875

G

cytochrome P450, family 2, subfamily b, polypeptide 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP2B10 mRNA

NCBI chr 7:25,597,083...25,626,049
Ensembl chr 7:25,597,045...25,626,049

G

cytochrome P450, family 2, subfamily b, polypeptide 13

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2B13 mRNA

NCBI chr 7:25,760,813...25,795,622
Ensembl chr 7:25,760,922...25,795,622

G

cytochrome P450, family 2, subfamily c, polypeptide 23

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP2C23 mRNA

NCBI chr19:43,993,461...44,017,695
Ensembl chr19:43,993,461...44,017,647

G

cytochrome P450, family 2, subfamily c, polypeptide 29

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C29 mRNA

NCBI chr19:39,275,541...39,319,157
Ensembl chr19:39,257,849...39,319,157

G

cytochrome P450, family 2, subfamily c, polypeptide 38

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C38 mRNA

NCBI chr19:39,379,109...39,451,519
Ensembl chr19:39,378,000...39,451,519

G

cytochrome P450, family 2, subfamily c, polypeptide 40

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C40 mRNA

NCBI chr19:39,755,517...39,801,258
Ensembl chr19:39,755,515...39,801,258

G

cytochrome P450, family 2, subfamily c, polypeptide 50

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C50 mRNA

NCBI chr19:40,078,123...40,102,399
Ensembl chr19:40,078,132...40,102,394

G

cytochrome P450, family 2, subfamily c, polypeptide 55

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C55 mRNA

NCBI chr19:38,995,384...39,031,134
Ensembl chr19:38,995,463...39,031,137

G

cytochrome P450, family 2, subfamily c, polypeptide 65

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C65 mRNA

NCBI chr19:39,049,450...39,082,392
Ensembl chr19:39,049,459...39,082,388

G

cytochrome P450, family 2, subfamily c, polypeptide 66

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C66 mRNA

NCBI chr19:39,102,342...39,175,200
Ensembl chr19:39,102,342...39,175,516

G

cytochrome P450, family 2, subfamily c, polypeptide 67

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C67 mRNA

NCBI chr19:39,597,288...39,637,497
Ensembl chr19:39,597,286...39,637,495

G

cytochrome P450, family 2, subfamily c, polypeptide 68

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C68 mRNA

NCBI chr19:39,677,280...39,729,545
Ensembl chr19:39,677,278...39,729,498

G

cytochrome P450, family 2, subfamily c, polypeptide 69

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C69 mRNA

NCBI chr19:39,831,104...39,875,213
Ensembl chr19:39,831,258...39,875,243

G

cytochrome P450, family 2, subfamily d, polypeptide 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2D10 mRNA

NCBI chr15:82,287,046...82,291,449
Ensembl chr15:82,287,047...82,291,396

G

cytochrome P450, family 2, subfamily d, polypeptide 11

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2D11 mRNA

NCBI chr15:82,273,355...82,278,223
Ensembl chr15:82,273,355...82,278,223

G

cytochrome P450, family 2, subfamily d, polypeptide 12

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2D12 mRNA

NCBI chr15:82,439,244...82,443,614
Ensembl chr15:82,439,273...82,444,604

G

cytochrome P450, family 2, subfamily d, polypeptide 26

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2D26 mRNA

NCBI chr15:82,674,308...82,678,653
Ensembl chr15:82,674,302...82,678,495

G

cytochrome P450, family 2, subfamily d, polypeptide 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2D9 mRNA

NCBI chr15:82,336,578...82,341,028
Ensembl chr15:82,317,638...82,341,046

G

cytochrome P450, family 2, subfamily e, polypeptide 1

decreases activity
multiple interactions

Dextran Sulfate results in decreased activity of CYP2E1 protein
[Dextran Sulfate results in decreased activity of CYP2E1 protein] which results in decreased chemical synthesis of 6-hydroxychlorzoxazone

NCBI chr 7:140,343,732...140,354,903
Ensembl chr 7:140,343,652...140,354,900

G

cytochrome P450, family 2, subfamily j, polypeptide 13

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2J13 mRNA

NCBI chr 4:95,930,897...95,965,803
Ensembl chr 4:95,915,771...95,965,783

G

cytochrome P450, family 2, subfamily j, polypeptide 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2J6 mRNA

NCBI chr 4:96,404,375...96,449,835
Ensembl chr 4:96,404,375...96,441,898

G

cytochrome P450, family 2, subfamily j, polypeptide 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2J8 mRNA

NCBI chr 4:96,332,187...96,395,634
Ensembl chr 4:96,332,833...96,395,623

G

cytochrome P450, family 2, subfamily j, polypeptide 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2J9 mRNA

NCBI chr 4:96,456,661...96,480,748
Ensembl chr 4:96,456,666...96,479,815

G

cytochrome P450, family 2, subfamily r, polypeptide 1

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2R1 mRNA; Cholecalciferol inhibits the reaction [Dextran Sulfate results in decreased expression of CYP2R1 protein]

PMID:29950665 PMID:38588969

NCBI chr 7:114,149,358...114,162,283
Ensembl chr 7:114,148,917...114,162,207

G

cytochrome P450, family 2, subfamily s, polypeptide 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2S1 mRNA

NCBI chr 7:25,501,894...25,515,950
Ensembl chr 7:25,501,900...25,516,338

G

cytochrome P450, family 3, subfamily a, polypeptide 11

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP3A11 mRNA

NCBI chr 5:145,791,417...145,816,664
Ensembl chr 5:145,791,236...145,816,774

G

cytochrome P450, family 3, subfamily a, polypeptide 13

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP3A13 mRNA

NCBI chr 5:137,891,195...137,923,872
Ensembl chr 5:137,891,194...137,919,881

G

cytochrome P450, family 3, subfamily a, polypeptide 16

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP3A16 mRNA

NCBI chr 5:145,373,119...145,406,550
Ensembl chr 5:145,373,119...145,406,533

G

cytochrome P450, family 4, subfamily a, polypeptide 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP4A10 mRNA

NCBI chr 4:115,375,484...115,390,846
Ensembl chr 4:115,375,461...115,390,846

G

cytochrome P450, family 4, subfamily a, polypeptide 14

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP4A14 mRNA

NCBI chr 4:115,343,397...115,353,355
Ensembl chr 4:115,343,397...115,353,339

G

cytochrome P450, family 4, subfamily b, polypeptide 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP4B1 mRNA

NCBI chr 4:115,481,895...115,504,918
Ensembl chr 4:115,481,922...115,504,920

G

cytochrome P450, family 4, subfamily f, polypeptide 13

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP4F13 mRNA

NCBI chr17:33,143,662...33,166,389
Ensembl chr17:33,143,662...33,166,376

G

cytochrome P450, family 4, subfamily f, polypeptide 14

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP4F14 mRNA

NCBI chr17:33,122,331...33,136,353
Ensembl chr17:33,124,044...33,136,316

G

cytochrome P450, family 4, subfamily f, polypeptide 17

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP4F17 mRNA

NCBI chr17:32,725,404...32,749,132
Ensembl chr17:32,725,024...32,749,117

G

cytochrome P450, family 4, subfamily f, polypeptide 39

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP4F39 mRNA

NCBI chr17:32,671,670...32,712,294
Ensembl chr17:32,671,697...32,712,294

G

cytochrome P450, family 4, subfamily f, polypeptide 40

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP4F40 mRNA

NCBI chr17:32,877,860...32,895,893
Ensembl chr17:32,877,874...32,895,888

G

cytochrome P450, family 7, subfamily a, polypeptide 1

decreases expression

Dextran Sulfate results in decreased expression of CYP7A1 mRNA

NCBI chr 4:6,265,612...6,275,632
Ensembl chr 4:6,265,612...6,275,633

G

cytochrome P450, family 7, subfamily b, polypeptide 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP7B1 mRNA

NCBI chr 3:18,126,108...18,298,054
Ensembl chr 3:18,126,114...18,297,502

G

death-associated protein kinase 3

multiple interactions
decreases expression

evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of DAPK3 protein]

NCBI chr10:81,018,821...81,029,031
Ensembl chr10:81,018,839...81,029,031

G

dihydrolipoamide branched chain transacylase E2

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of DBT protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of DBT protein]

NCBI chr 3:116,306,776...116,343,630
Ensembl chr 3:116,306,719...116,343,630

G

decorin

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DCN mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of DCN protein]

PMID:29950665 PMID:32272095

NCBI chr10:97,315,362...97,354,025
Ensembl chr10:97,315,471...97,354,005

G

dynactin 3

multiple interactions
decreases expression

evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of DCTN3 protein]

NCBI chr 4:41,714,798...41,723,213
Ensembl chr 4:41,714,798...41,723,170

G

discoidin domain receptor family, member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DDR2 mRNA

NCBI chr 1:169,799,874...169,938,525
Ensembl chr 1:169,799,876...169,938,331

G

DEAD box helicase 23

increases expression
multiple interactions

Dextran Sulfate results in increased expression of DDX23 protein
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of DDX23 protein]

NCBI chr15:98,543,012...98,560,808
Ensembl chr15:98,543,015...98,560,775

G

DEPP1 autophagy regulator

increases expression

Dextran Sulfate results in increased expression of DEPP1 mRNA

NCBI chr 6:116,627,645...116,629,808
Ensembl chr 6:116,627,570...116,629,755

G

Der1-like domain family, member 3

increases expression

Dextran Sulfate results in increased expression of DERL3 mRNA

NCBI chr10:75,729,232...75,731,775
Ensembl chr10:75,729,247...75,731,775

G

diacylglycerol kinase, beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DGKB mRNA

NCBI chr12:37,930,169...38,684,238
Ensembl chr12:37,867,725...38,684,238

G

diacylglycerol kinase, iota

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DGKI mRNA

NCBI chr 6:36,814,316...37,281,034
Ensembl chr 6:36,822,957...37,277,119

G

24-dehydrocholesterol reductase

decreases expression

Dextran Sulfate results in decreased expression of DHCR24 mRNA

NCBI chr 4:106,418,279...106,446,310
Ensembl chr 4:106,418,235...106,446,310

G

dihydrodiol dehydrogenase

multiple interactions
decreases expression

evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of DHDH protein]

NCBI chr 7:45,122,380...45,138,312
Ensembl chr 7:45,120,411...45,138,229

G

dihydroorotate dehydrogenase

increases expression
multiple interactions

Dextran Sulfate results in increased expression of DHODH protein
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of DHODH protein]

NCBI chr 8:110,319,876...110,335,330
Ensembl chr 8:110,317,975...110,335,305

G

dehydrogenase/reductase 9

increases expression

Dextran Sulfate results in increased expression of DHRS9 mRNA

NCBI chr 2:69,210,806...69,233,430
Ensembl chr 2:69,210,789...69,234,877

G

dehydrogenase/reductase X linked

increases expression

Dextran Sulfate results in increased expression of DHRSX mRNA

NCBI chr 4:156,390,105...156,410,432

G

diaphanous related formin 1

multiple interactions
increases expression

evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of DIAPH1 protein]

NCBI chr18:37,976,654...38,068,573
Ensembl chr18:37,976,654...38,068,529

G

dickkopf WNT signaling pathway inhibitor 2

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of DKK2 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of DKK2 mRNA]

NCBI chr 3:131,791,027...131,886,065
Ensembl chr 3:131,791,053...131,886,065

G

delta like non-canonical Notch ligand 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DLK1 mRNA

NCBI chr12:109,418,411...109,429,262
Ensembl chr12:109,418,749...109,429,262

G

dystrophia myotonica-protein kinase

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of DMPK mRNA

NCBI chr 7:18,817,571...18,827,746
Ensembl chr 7:18,817,774...18,827,746

G

doublesex and mab-3 related transcription factor like family A1

decreases expression

Dextran Sulfate results in decreased expression of DMRTA1 mRNA

NCBI chr 4:89,576,435...89,583,003
Ensembl chr 4:89,567,673...89,583,009

G

dystrophia myotonica-containing WD repeat motif

increases expression

Dextran Sulfate results in increased expression of DMWD mRNA

NCBI chr 7:18,810,002...18,816,701
Ensembl chr 7:18,810,152...18,816,701

G

DnaJ heat shock protein family (Hsp40) member B4

multiple interactions
decreases expression

evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of DNAJB4 protein]

NCBI chr 3:151,887,217...151,915,720
Ensembl chr 3:151,884,148...151,915,939

G

DnaJ heat shock protein family (Hsp40) member C10

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of DNAJC10 protein]

NCBI chr 2:80,145,790...80,184,399
Ensembl chr 2:80,145,810...80,184,387

G

dynamin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DNM1 mRNA

NCBI chr 2:32,198,483...32,243,361
Ensembl chr 2:32,198,483...32,243,350

G

dynamin 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DNM3 mRNA

NCBI chr 1:161,810,022...162,305,890
Ensembl chr 1:161,810,022...162,305,603

G

dedicator of cytokinesis 1

multiple interactions
decreases expression

evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of DOCK1 protein]

NCBI chr 7:134,272,416...134,775,376
Ensembl chr 7:134,272,383...134,775,368

G

docking protein 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DOK2 mRNA

NCBI chr14:71,003,336...71,015,934
Ensembl chr14:71,003,476...71,015,935

G

dipeptidase 1

multiple interactions
increases expression

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of DPEP1 protein; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of DPEP1 protein]

PMID:32272095 PMID:35999755

NCBI chr 8:123,913,069...123,928,551
Ensembl chr 8:123,912,981...123,928,551

G

dipeptidase 2

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of DPEP2 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DPEP2 mRNA

PMID:29950665 PMID:35999755

NCBI chr 8:106,711,577...106,732,658
Ensembl chr 8:106,711,576...106,718,391
Ensembl chr 8:106,711,576...106,718,391

G

dihydropyrimidine dehydrogenase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DPYD mRNA

NCBI chr 3:118,355,758...119,226,573
Ensembl chr 3:118,355,778...119,226,573

G

DR1 associated protein 1

increases expression

Dextran Sulfate results in increased expression of DRAP1 mRNA

NCBI chr19:5,472,832...5,475,007
Ensembl chr19:5,472,833...5,475,007

G

dopamine receptor D4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DRD4 mRNA

NCBI chr 7:140,871,931...140,874,868
Ensembl chr 7:140,871,919...140,876,377

G

dopamine receptor D5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DRD5 mRNA

NCBI chr 5:38,476,742...38,479,868
Ensembl chr 5:38,476,710...38,479,861

G

deltex 1, E3 ubiquitin ligase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DTX1 mRNA

NCBI chr 5:120,818,268...120,850,879
Ensembl chr 5:120,818,267...120,849,992

G

dual oxidase maturation factor 2

increases expression

Dextran Sulfate results in increased expression of DUOXA2 mRNA

NCBI chr 2:122,129,381...122,133,088
Ensembl chr 2:122,129,381...122,133,366

G

dual specificity phosphatase 1

multiple interactions
increases expression

DUSP1 protein affects the reaction [Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of IL6 protein]]; DUSP1 protein affects the reaction [Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of TNF protein]]; DUSP1 protein affects the reaction [Butylated Hydroxyanisole inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]]; DUSP1 protein affects the reaction [Resveratrol affects the reaction [Dextran Sulfate affects the expression of IL6 protein]]; DUSP1 protein affects the reaction [Resveratrol affects the reaction [Dextran Sulfate affects the expression of TNF protein]]; DUSP1 protein affects the reaction [Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]]; DUSP1 protein affects the susceptibility to [Azoxymethane co-treated with Dextran Sulfate]
Dextran Sulfate results in increased expression of DUSP1 mRNA

PMID:30844440 PMID:35093514

NCBI chr17:26,724,565...26,727,446
Ensembl chr17:26,724,564...26,781,102

G

enoyl-Coenzyme A delta isomerase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ECI1 mRNA

NCBI chr17:24,645,657...24,658,290
Ensembl chr17:24,645,615...24,658,322

G

Ecm29 proteasome adaptor and scaffold

decreases expression
increases expression
multiple interactions

Dextran Sulfate results in decreased expression of ECPAS protein
Dextran Sulfate results in increased expression of ECPAS protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ECPAS protein]; evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of ECPAS protein]

PMID:32272095 PMID:35362542

NCBI chr 4:58,797,234...58,917,748
Ensembl chr 4:58,798,911...58,912,749

G

ectodysplasin-A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDA mRNA

NCBI chr X:99,019,212...99,444,366
Ensembl chr X:99,019,212...99,444,368

G

ectodysplasin A2 receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDA2R mRNA

NCBI chr X:96,375,936...96,420,786
Ensembl chr X:96,377,446...96,420,822

G

endothelial differentiation-related factor 1

increases expression

Dextran Sulfate results in increased expression of EDF1 mRNA

NCBI chr 2:25,447,838...25,452,096
Ensembl chr 2:25,447,859...25,452,094

G

endothelin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDN1 mRNA

NCBI chr13:42,454,952...42,461,466
Ensembl chr13:42,454,952...42,461,466

G

endothelin 2

increases expression
multiple interactions

Dextran Sulfate results in increased expression of EDN2 protein
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of EDN2 mRNA

PMID:16216902 PMID:29950665

NCBI chr 4:120,018,403...120,024,557
Ensembl chr 4:120,018,403...120,024,557

G

endothelin receptor type A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDNRA mRNA

NCBI chr 8:78,389,658...78,451,081
Ensembl chr 8:78,389,660...78,451,093

G

eukaryotic translation elongation factor 1 gamma

decreases expression

Dextran Sulfate results in decreased expression of EEF1G protein

NCBI chr19:8,944,405...8,955,544
Ensembl chr19:8,944,405...8,955,843

G

epidermal growth factor-containing fibulin-like extracellular matrix protein 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EFEMP2 mRNA

NCBI chr19:5,523,974...5,532,548
Ensembl chr19:5,523,982...5,532,545

G

EF hand domain containing 2

increases expression

Dextran Sulfate results in increased expression of EFHD2 mRNA

NCBI chr 4:141,585,453...141,602,231
Ensembl chr 4:141,585,453...141,602,231

G

ephrin A1

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in decreased expression of EFNA1 mRNA

NCBI chr 3:89,179,037...89,188,258
Ensembl chr 3:89,179,040...89,188,449

G

egl-9 family hypoxia-inducible factor 2

increases expression

Dextran Sulfate results in increased expression of EGLN2 mRNA

NCBI chr 7:26,858,083...26,866,227
Ensembl chr 7:26,858,083...26,866,227

G

EH-domain containing 1

decreases expression

Dextran Sulfate results in decreased expression of EHD1 protein

NCBI chr19:6,326,926...6,350,126
Ensembl chr19:6,326,755...6,350,126

G

EH-domain containing 4

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of EHD4 protein
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of EHD4 protein

NCBI chr 2:119,919,958...119,985,028
Ensembl chr 2:119,919,656...119,985,087

G

enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme A dehydrogenase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of EHHADH mRNA

NCBI chr16:21,580,035...21,606,589
Ensembl chr16:21,580,037...21,606,557

G

euchromatic histone lysine N-methyltransferase 2

increases expression

Dextran Sulfate results in increased expression of EHMT2 mRNA

NCBI chr17:35,117,427...35,133,049
Ensembl chr17:35,117,445...35,133,028

G

eukaryotic translation initiation factor 2-alpha kinase 2

multiple interactions
increases phosphorylation

EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased activity of CASP3 protein]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased phosphorylation of RELA protein]; GW 506033X inhibits the reaction [Dextran Sulfate results in increased phosphorylation of EIF2AK2 protein]

NCBI chr17:79,157,933...79,190,001
Ensembl chr17:79,159,993...79,190,002

G

eukaryotic translation initiation factor 2B, subunit 5 epsilon

increases expression
multiple interactions

Dextran Sulfate results in increased expression of EIF2B5 protein
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of EIF2B5 protein]

NCBI chr16:20,317,544...20,328,073
Ensembl chr16:20,317,567...20,328,073

G

eukaryotic translation initiation factor 3, subunit A

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of EIF3A mRNA

NCBI chr19:60,749,554...60,779,131
Ensembl chr19:60,749,555...60,779,096

G

eukaryotic translation initiation factor 5A

decreases expression

Dextran Sulfate results in decreased expression of EIF5A protein

NCBI chr11:69,807,538...69,812,784
Ensembl chr11:69,807,540...69,812,784

G

eukaryotic translation initiation factor 5B

increases expression

Dextran Sulfate results in increased expression of EIF5B mRNA

NCBI chr 1:38,037,091...38,094,660
Ensembl chr 1:38,037,091...38,094,660

G

elastase, neutrophil expressed

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ELANE mRNA

NCBI chr10:79,722,146...79,724,050
Ensembl chr10:79,722,081...79,724,049

G

engulfment and cell motility 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ELMO2 mRNA

NCBI chr 2:165,129,951...165,168,421
Ensembl chr 2:165,129,951...165,168,399

G

ER membrane protein complex subunit 2

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of EMC2 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of EMC2 protein]

NCBI chr15:43,340,603...43,391,174
Ensembl chr15:43,340,625...43,391,159

G

epithelial membrane protein 2

decreases expression

Dextran Sulfate results in decreased expression of EMP2 mRNA

NCBI chr16:10,099,613...10,131,832
Ensembl chr16:10,099,613...10,131,832

G

endoglin

decreases expression

Dextran Sulfate results in decreased expression of ENG mRNA

NCBI chr 2:32,536,607...32,572,681
Ensembl chr 2:32,536,607...32,572,681

G

enolase 1, alpha non-neuron

decreases expression

Dextran Sulfate results in decreased expression of ENO1 protein

NCBI chr 4:150,321,165...150,333,336
Ensembl chr 4:150,321,178...150,333,336
Ensembl chr18:150,321,178...150,333,336

G

enolase 2, gamma neuronal

multiple interactions
increases expression

evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of ENO2 protein]

NCBI chr 6:124,737,018...124,746,489
Ensembl chr 6:124,737,016...124,746,636

G

enolase 3, beta muscle

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of ENO3 protein
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of ENO3 protein; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ENO3 protein]

PMID:32272095 PMID:35999755

NCBI chr11:70,543,973...70,553,339
Ensembl chr11:70,548,028...70,553,339

G

glutamyl aminopeptidase

increases expression
multiple interactions

Dextran Sulfate results in increased expression of ENPEP protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ENPEP protein]

NCBI chr 3:129,062,826...129,126,398
Ensembl chr 3:129,062,824...129,126,369

G

ectonucleoside triphosphate diphosphohydrolase 5

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in decreased expression of ENTPD5 mRNA

NCBI chr12:84,420,649...84,455,803
Ensembl chr12:84,420,631...84,455,803

G

E1A binding protein p300

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EP300 mRNA

NCBI chr15:81,470,329...81,536,273
Ensembl chr15:81,469,552...81,536,278

G

epoxide hydrolase 1, microsomal

decreases expression

Dextran Sulfate results in decreased expression of EPHX1 mRNA

NCBI chr 1:180,817,121...180,845,134
Ensembl chr 1:180,803,775...180,848,469

G

erb-b2 receptor tyrosine kinase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ERBB2 mRNA

NCBI chr11:98,303,310...98,328,542
Ensembl chr11:98,303,296...98,328,542

G

erb-b2 receptor tyrosine kinase 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ERBB3 mRNA

NCBI chr10:128,403,392...128,425,504
Ensembl chr10:128,403,392...128,425,521

G

erb-b2 receptor tyrosine kinase 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ERBB4 mRNA

NCBI chr 1:68,071,063...69,147,756
Ensembl chr 1:68,071,345...69,147,218

G

epiregulin

decreases response to substance
increases expression

EREG protein results in decreased susceptibility to Dextran Sulfate
dextran sodium sulfate increases expression of Ereg protein in colonic mucosa

CTD
RGD

PMID:15456865 PMID:20498653

NCBI chr 5:91,222,476...91,241,508
Ensembl chr 5:91,222,481...91,241,505

G

endoplasmic reticulum metallopeptidase 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of ERMP1 protein
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of ERMP1 protein]

NCBI chr19:29,587,276...29,625,815
Ensembl chr19:29,585,614...29,625,815

G

endoplasmic reticulum oxidoreductase 1 alpha

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of ERO1A protein
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of ERO1A protein]

NCBI chr14:45,520,544...45,556,029
Ensembl chr14:45,520,544...45,556,228

G

ERBB receptor feedback inhibitor 1

increases expression

Dextran Sulfate results in increased expression of ERRFI1 mRNA

NCBI chr 4:150,938,253...150,953,346
Ensembl chr 4:150,938,376...150,953,349

G

endothelial cell-specific adhesion molecule

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ESAM mRNA

NCBI chr 9:37,439,385...37,449,615
Ensembl chr 9:37,439,374...37,449,615

G

estrogen receptor 1 (alpha)

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of ESR1 mRNA
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ESR1 mRNA

PMID:29950665 PMID:30270565

NCBI chr10:4,561,989...4,955,633
Ensembl chr10:4,561,593...4,955,614

G

estrogen receptor 2 (beta)

multiple interactions

Dextran Sulfate promotes the reaction [Zearalenone results in increased expression of ESR2 mRNA]

NCBI chr12:76,167,193...76,224,033
Ensembl chr12:76,167,193...76,224,033

G

Ena-vasodilator stimulated phosphoprotein

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EVL mRNA

NCBI chr12:108,520,942...108,654,775
Ensembl chr12:108,520,979...108,654,775

G

Ewing sarcoma breakpoint region 1

increases expression

Dextran Sulfate results in increased expression of EWSR1 mRNA

NCBI chr11:5,019,687...5,049,314
Ensembl chr11:5,019,689...5,049,266

G

coagulation factor X

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F10 mRNA

NCBI chr 8:13,087,308...13,106,676
Ensembl chr 8:13,087,308...13,106,676

G

coagulation factor XI

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of F11 protein

NCBI chr 8:45,693,696...45,715,092
Ensembl chr 8:45,694,211...45,715,068

G

F11 receptor

multiple interactions
increases expression

evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of F11R protein]

NCBI chr 1:171,265,129...171,292,161
Ensembl chr 1:171,265,103...171,292,171

G

coagulation factor XIII, A1 subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F13A1 mRNA

NCBI chr13:37,051,150...37,234,220
Ensembl chr13:37,051,152...37,234,220

G

coagulation factor II thrombin receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F2R mRNA

NCBI chr13:95,738,288...95,754,974
Ensembl chr13:95,738,311...95,754,995

G

F2R like trypsin receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of F2RL1 mRNA

NCBI chr13:95,648,226...95,661,748
Ensembl chr13:95,648,240...95,661,735

G

coagulation factor V

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F5 mRNA

NCBI chr 1:163,979,396...164,048,539
Ensembl chr 1:163,979,407...164,047,846

G

fatty acid amide hydrolase

multiple interactions

[Serotonin co-treated with Dextran Sulfate] results in decreased expression of FAAH protein

NCBI chr 4:115,853,866...115,876,034
Ensembl chr 4:115,824,342...115,875,123

G

fatty acid binding protein 4, adipocyte

multiple interactions
increases expression

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of FABP4 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of FABP4 protein]

PMID:26271895 PMID:32272095

NCBI chr 3:10,269,406...10,273,653
Ensembl chr 3:10,269,148...10,273,636

G

fatty acid binding protein 5, epidermal

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of FABP5 protein
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of FABP5 protein]

NCBI chr 3:10,077,645...10,081,670
Ensembl chr 3:10,077,608...10,081,667

G

fatty acid binding protein 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FABP6 mRNA

NCBI chr11:43,486,867...43,492,389
Ensembl chr11:43,486,876...43,492,367

G

fatty acid desaturase 1

decreases expression

Dextran Sulfate results in decreased expression of FADS1 mRNA

NCBI chr19:10,160,245...10,174,238
Ensembl chr19:10,160,252...10,174,241

G

fatty acid desaturase 2

decreases expression

Dextran Sulfate results in decreased expression of FADS2 mRNA

NCBI chr19:10,040,129...10,078,867
Ensembl chr19:10,040,129...10,079,110

G

family with sequence similarity 136, member A

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of FAM136A protein
evodiamine inhibits the reaction [Dextran Sulfate results in decreased expression of FAM136A protein]

NCBI chr 6:86,342,453...86,347,040
Ensembl chr 6:86,342,628...86,347,040

G

family with sequence similarity 229, member A

increases expression

Dextran Sulfate results in increased expression of FAM229A mRNA

NCBI chr 4:129,384,983...129,385,749
Ensembl chr 4:129,384,983...129,385,749

G

family with sequence similarity 234, member A

multiple interactions
increases expression

evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of FAM234A protein]

NCBI chr17:26,431,673...26,463,216
Ensembl chr17:26,430,796...26,463,216

G

family with sequence similarity 50, member B

increases expression

Dextran Sulfate results in increased expression of FAM50B mRNA

NCBI chr13:34,918,833...34,931,605
Ensembl chr13:34,918,833...34,931,606

G

family with sequence similarity 98, member B

increases expression

Dextran Sulfate results in increased expression of FAM98B mRNA

NCBI chr 2:117,080,150...117,102,021
Ensembl chr 2:117,080,220...117,102,021

G

FAU ubiquitin like and ribosomal protein S30 fusion

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of FAU protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of FAU protein]

NCBI chr19:6,107,977...6,109,554
Ensembl chr19:6,107,874...6,109,554

G

filamin binding LIM protein 1

increases expression
multiple interactions

Dextran Sulfate results in increased expression of FBLIM1 protein
evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of FBLIM1 protein]

NCBI chr 4:141,303,373...141,333,351
Ensembl chr 4:141,303,373...141,333,407

G

fibulin 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FBLN2 mRNA

NCBI chr 6:91,189,442...91,249,522
Ensembl chr 6:91,189,437...91,249,522

G

fibulin 5

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FBLN5 mRNA
Dextran Sulfate results in decreased expression of FBLN5 mRNA

PMID:29950665 PMID:35093514

NCBI chr12:101,712,820...101,785,541
Ensembl chr12:101,712,824...101,785,314

G

fibrillin 1

multiple interactions
increases expression
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FBN1 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of FBN1 protein]; evodiamine inhibits the reaction [Dextran Sulfate results in increased expression of FBN1 protein]

PMID:29950665 PMID:32272095 PMID:35362542

NCBI chr 2:125,142,514...125,348,417
Ensembl chr 2:125,142,514...125,349,913

G

F-box protein 2

increases expression

Dextran Sulfate results in increased expression of FBXO2 mRNA

NCBI chr 4:148,244,605...148,250,874
Ensembl chr 4:148,245,078...148,250,881

G

Fc receptor, IgE, high affinity I, gamma polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCER1G mRNA

NCBI chr 1:171,057,141...171,061,918
Ensembl chr 1:171,057,141...171,061,934

G

Fc receptor, IgG, high affinity I

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR1 mRNA

NCBI chr 3:96,190,225...96,201,285
Ensembl chr 3:96,190,225...96,201,285

G

Fc receptor, IgG, low affinity IIb

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR2B mRNA

NCBI chr 1:170,786,186...170,804,141
Ensembl chr 1:170,786,186...170,804,116

G

Fc receptor, IgG, low affinity III

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR3 mRNA

NCBI chr 1:170,878,738...170,893,477
Ensem